key: cord-0755987-t95de283
authors: Oz, Murat; Lorke, Dietrich Ernst; Kabbani, Nadine
title: A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor
date: 2020-12-01
journal: Pharmacol Ther
DOI: 10.1016/j.pharmthera.2020.107750
sha: bf3aea3580cd939fdbf95e42a78462560287543a
doc_id: 755987
cord_uid: t95de283

The recent emergence of coronavirus disease-2019 (COVID-19) as a global pandemic has prompted scientists to address an urgent need for defining mechanisms of disease pathology and treatment. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19, employs angiotensin converting enzyme 2 (ACE2) as its primary target for cell surface attachment and likely entry into the host cell. Thus, understanding factors that may regulate the expression and function of ACE2 in the healthy and diseased body is critical for clinical intervention. Over 66% of all adults in the United States are currently using a prescription drug and while earlier findings have focused on possible upregulation of ACE2 expression through the use of renin angiotensin system (RAS) inhibitors, mounting evidence suggests that various other widely administered drugs used in the treatment of hypertension, heart failure, diabetes mellitus, hyperlipidemias, coagulation disorders, and pulmonary disease may also present a varied risk for COVID-19. Specifically, we summarize mechanisms on how heparin, statins, steroids and phytochemicals, besides their established therapeutic effects, may also interfere with SARS-CoV-2 viral entry into cells. We also describe evidence on the effect of several vitamins, phytochemicals, and naturally occurring compounds on ACE2 expression and activity in various tissues and disease models. This comprehensive review aims to provide a timely compendium on the potential impact of commonly prescribed drugs and pharmacologically active compounds on COVID-19 pathology and risk through regulation of ACE2 and RAS signaling.

The recent emergence of coronavirus disease-2019 (COVID-19) as a pandemic affecting millions of individuals has raised great concern throughout the world and has spurred an urgent need for treatments. In order to enter the host cell, the causative agent "severe acute respiratory syndrome coronavirus-2" (SARS-CoV-2) binds to angiotensin converting enzyme 2 (ACE2), which is widely expressed throughout the body, including lung alveolar epithelial cells, nasal and oral mucosal cells, vascular endothelium, and enterocytes of the small intestine . Higher ACE2 expression is correlated with higher pseudotype SARS-CoV-2 and SARS-CoV viral infectivity (Hofmann et al., 2004; H. P. Jia et al., 2005; W. Li et al., 2007; Ou et al., 2020) , suggesting that increased ACE2 levels may predispose individuals to SARS-CoV-2 transmission. Since ACE inhibitors (ACE-Inhs.) and Angiotensin 1-Receptor (AT1-R) blockers (ARBs) have been reported to increase ACE2 expression, concerns have been raised regarding the safety of these drugs in patients exposed to SARS-CoV-2. Thus, these concerns are mainly based on the hypothesis that such medications may raise the expression of ACE2 and increase the susceptibility of patients to SARS-CoV-2 (Peron & Nakaya, 2020) . Because both an ACE inhibitor (lisinopril) and an AT1-R blocker (losartan) are among the 10 most commonly used drugs with a combined 155 million prescriptions per year in the USA alone (Zolk et al., 2020) , patients receiving these drugs would represent a substantial group of people at risk. This article reviews the effects not only of ACE-Inhs. and ARBs, but also of other drugs on the expression and activity of ACE2. In addition, the pharmacological effects of these drugs and naturally occurring compounds are discussed in the context of COVID-19. Thus, the focus of this review is neither the treatment of COVID-19 nor the regulation of ACE2 in specific disease conditions, but the regulation of ACE2 by the many drugs, pharmacologically active compounds and naturally occurring substances used in society today.

ACE2, a homologue of ACE, was discovered two decades ago by two independently working research groups, Donoghue et al. (2000) and Tipnis et al. (2000) . Like ACE, ACE2 is an integral membrane protein and zinc metallopeptidase with an amino acid sequence that is 42% identical to ACE. While ACE contains two catalytic domains, ACE2 has only one. Importantly, ACE-Inhs. belonging to the classic "pril" group used in the treatment of cardiovascular diseases do not affect the enzymatic functions of ACE2 (Donoghue et al., 2000; Tipnis et al., 2000) . Structural and functional features and topographical characteristics of ACE2 have been reviewed earlier (Kuba, Imai, Ohto-Nakanishi, & Penninger, 2010; Turner, 2015) . The major functional difference between ACE and ACE2 is that ACE produces Angiotensin II (Ang-II), whereas ACE2 degrades this peptide. Specifically, ACE2 functions as a carboxypeptidase removing a single C-terminal amino acid from the octapeptide Ang-II, generating the heptapeptide Angiotensin-(1-7) [Ang-(1-7)] or, much less efficiently, from the decapeptide Angiotensin I (Ang-I) forming the nonapeptide Angiotensin-(1-9) ]. In contrast, ACE acts as a carboxydipeptidase (peptidyldipeptidase) removing the C-terminal dipeptide from Ang-I to form Ang-II. Furthermore, whereas ACE metabolizes bradykinin to [des-Arg9]-bradykinin, ACE2 degrades [des-Arg9]-bradykinin to pharmacologically inactive breakdown products (Tipnis et al., 2000) . Other substrates for ACE2, at least in vitro, include apelin-13/17, neurotensin (1-11), dynorphin A (1-13), amyloid-β peptides, β-casomorphin-(1-7), and ghrelin (Turner, 2015; Vickers et al., 2002) .

In most tissues, ACE2 is found in its membrane-bound form, which contains an extracellular segment anchored to the plasma membrane through a transmembrane domain. This enzymatically active N-terminal ecto-domain can be cleaved by a membranebound protease, also called secretase (or sheddase), and released into the surrounding extracellular space. Thus, some fraction of membrane bound ACE2 is shed into the circulation as soluble ACE2 and can be detected in plasma, cerebrospinal fluid, and urine samples. In its soluble form, however, ACE2 is found in very low concentrations in the circulation (Epelman et al., 2008; Rice et al., 2006) . While serum ACE levels were reported to be 7 nM (Rice et al., 2006) , the ACE2 concentration was found to be 200-fold lower (33 pM) in over 500 subjects. In recent years, it has become increasingly apparent that the proteolytic shedding of cell surface ACE2 is an important mechanism regulating its expression, functions, and soluble concentrations in biological fluids (J. Xu et al., 2017) . The major protease mediating ectodomain shedding of ACE2 is a type I transmembrane protein belonging to the adamalysin subfamily of Zndependent metalloproteases ("A Disintegrin And Metalloprotease 17"; ADAM17). Since this protease also mediates extracellular domain shedding and activation of the proinflammatory cytokine TNF-α (Black et al., 1997; Moss et al., 1997) , it is also known as "tumor necrosis factor-α (TNF-α) cleavage enzyme" (TACE) (Lambert et al., 2005; Patel et al., 2014) . Pharmacological agents, e.g., rosiglitazone (Chodavarapu et al., 2013) and the vitamin D analog paricalcitol (Riera et al., 2016) , as well as endogenous peptides, e.g., Ang-II (Patel et al., 2014) and insulin (Salem, Grobe, & Elased, 2014) , regulate the activity of ADAM17. Several pathologies, such as hypertension, diabetes mellitus, renal failure (Chodavarapu et al., 2016; Salem, Grobe, & Elased, 2014; Somineni, Boivin, & Elased, 2014 J. Xu et al., 2016 , and SARS-CoV infections (Haga et al., 2008) are associated with significant alterations in ADAM17 activity. Importantly, soluble ACE2 levels in circulation and biological fluids are the result of a dynamic process determined not only by cell surface expression, but also by ACE2 shedding. Notably, soluble circulating ACE2 appears to serve as a biomarker in renal and cardiovascular diseases, such as hypertension, heart failure, and diabetes mellitus (Anguiano, Riera, Pascual, & Soler, 2017) .

ACE2, by converting Ang-I into Ang-(1-9), and Ang-II into Ang-(1-7), degrades Ang-I and Ang-II, thereby negatively regulating the reninangiotensin system (RAS) and mitigating the deleterious effects of these peptides (Fig. 1) . Thus, the enzymatic functions of ACE2 are of particular significance in pathological conditions where the RAS is overstimulated by Ang-I and Ang-II (Arendse et al., 2019; Chappell, 2016; Paz Ocaranza et al., 2020) . Biological actions of Ang-(1-7) are mediated mainly by the Mas receptor (MasR), and a vast array of its effects are opposite to those attributed to Ang-II activation of the Ang-II type 1 receptor (AT1-R) (Arendse et al., 2019; Santos et al., 2018) . can be degraded to Ang-(1-5) by ACE (Chappell, 2016) . In addition, Ang-(1-7) inhibits the enzymatic activity of ACE (Raffai, Khang, & Vanhoutte, 2014; Tom, de Vries, Saxena, & Danser, 2001) . Thus, Ang-(1-7) acts both as substrate and as inhibitor of ACE. Ang-(1-9) has also shown beneficial biological effects via the AT2-R that result in cardioprotection, vasodilation, and decreased platelet aggregation; however, expression of AT2-Rs is low in adults (Arendse et al., 2019; Paz Ocaranza et al., 2020) . Nevertheless, Ang-II binds with equal affinity (in the nM range) to AT1-Rs and AT2-Rs, and AT2-R density in tissues increases significantly in some physiological conditions, e.g., fetal development, pregnancy, and parturition, as well as in pathological conditions, e.g., inflammation, ischemia, diabetes, hypertension, and pulmonary fibrosis (Karnik et al., 2015; Kaschina, Namsolleck, & Unger, 2017; Sumners, Peluso, Haugaard, Bertelsen, & Steckelings, 2019) . Activation of AT2-Rs usually counterbalances the effects of AT1-Rs and induces antihypertensive, antioxidative, antiinflammatory, and anti-fibrotic effects (de Kloet, Steckelings, & Sumners, 2017; Karnik et al., 2015; Sumners, Peluso, Haugaard, Bertelsen, & Steckelings, 2019) . Thus, the ACE2/Ang-(1-7)/MasR axis, along with AT2-Rs, has emerged as a physiological antagonist that counter-regulates the activity of the classical RAS pathway (Arendse et al., 2019; Chappell, 2016; Santos et al., 2018) .

As a major driver of the ACE/Ang-II/AT1-R axis, Ang-II downregulates ACE2 expression by activating AT1-R-mediated upregulation of "extracellular signal-regulated kinase" (ERK)1/2 and p38 mitogenactivated protein (MAP) kinase in human tubular kidney cells (Koka et al., 2008) , rat aortic vascular smooth muscle cells (Gallagher, Ferrario, & Tallant, 2008a) , cardiomyocytes (Gallagher, Ferrario, & Tallant, 2008b) , and catecholaminergic neurons (L. Xiao, Haack, & Zucker, 2013) . In Neuro-2A cells transfected with ACE2, AT1-R activation by Ang-II leads to internalization and subsequent destruction of ACE2 in lysosomes (Deshotels, Xia, Sriramula, Lazartigues, & Filipeanu, 2014) . In addition, Ang-II activation of the AT1-R promotes ADAM17mediated proteolytic cleavage of ACE2 in COS7 cells (Mifune et al., 2005) , cardiomyocytes (Patel et al., 2014) and hypothalamic neurons (Xia, Sriramula, Chhabra, & Lazartigues, 2013; J. Xu, Sriramula, et al., 2017) . Furthermore, Ang-II stimulates phosphorylation of three MAP kinases, i.e., p38 kinase, ERK 1/2, and c-Jun N-terminal kinase (JNK) to mediate its actions. It also increases the production of transforming growth factor β 1 (TGF-β1), which further suppresses ACE2 expression (Chou, Chuang, Lu, & Guh, 2013; Su, Zimpelmann, & Burns, 2006) and promotes ADAM17 activation (Ohtsu et al., 2006) . Thus, Ang-II-induced down regulation of ACE2 expression, eventually leads to impaired conversion of Ang-II to Ang-(1-7) and causes further accumulation of Ang-II and RAS-mediated detrimental effects in a positive feedback cycle. Similar to Ang-II, another vasoconstrictive peptide, Endothelin-1, also downregulates ACE2 transcription by activating p38 MAP kinase and ERK1/2 pathways in human bronchial epithelial cells (H. Zhang, Li, Zeng, Wu, & Ou, 2013) and rat cardiomyocytes (Gallagher, Ferrario, & Tallant, 2008b) .

As opposed to Ang-II, Ang-(1-7) and atrial natriuretic peptide (ANP) do not affect ACE2 expression (Deshotels, Xia, Sriramula, Lazartigues, & Filipeanu, 2014) . However, both peptides counteract Ang-II-AT1-Rmediated down regulation of ACE2 by activating MAP kinase phosphatase in rat aortic vascular smooth muscle cells (Gallagher, Ferrario, & Tallant, 2008a) , astrocytes , and cardiomyocytes (Gallagher et al., 2008b) . In addition, Ang-(1-7) and ANP inhibit ADAM17 activity (X. Ma et al., 2016; Zhai et al., 2018) . In summary, while Ang-II downregulates ACE2 expression initiating a positive feedback mechanism leading to further elevation of Ang-II, Ang-(1-7) activates the Mas receptor and counteracts these cellular actions of Ang-II.

In addition to the RAS, ACE2 is involved in the regulation of the kinin-kallikrein system (KKS). Effector peptides of the KKS, mainly bradykinin (BK) and its active metabolite [des-Arg9]-BK (DABK), recognize two pharmacologically distinct G protein-coupled receptors: the B1 receptor, whose main agonist is DABK, and the B2 receptor, whose ligand is BK (Rhaleb, Yang, & Carretero, 2011) . The RAS enzymes ACE and ACE2 degrade BK and DABK, respectively ( Fig. 1) (Donoghue et al., 2000; Vickers et al., 2002) . In addition, Ang-(1-7) produced by ACE2 downregulates ACE activity (Tom, de Vries, Saxena, & Danser, 2001) and potentiates BK-induced vasodilatations (Raffai, Khang, & Vanhoutte, 2014) . Thus, downregulation of ACE2 activity by disease conditions, such as lung injury and SARS-CoV infections, may increase DABK levels. Over-activation of B1 receptors can contribute to the pathogenesis of these diseases. In an endotoxin-induced lung inflammation model, the loss of ACE2 function leads to an accumulation of DABK, an activation of B1 receptors, and the release of proinflammatory chemokines from airway epithelia. Examples of released chemokines are C-X-C motif chemokine 1 and 5, macrophage inflammatory protein-2, and cytokines, e.g., TNF-α. In this model, neutrophil infiltration as well as lung inflammation and injury have been increased (C. P. Sodhi et al., 2018) .

In clinical studies, commonly used antihypertensive medications, such as β-adrenergic receptor blockers (βARBs) and calcium channel blockers (CCBs), are not associated with changes in plasma or urine ACE2 levels (Furuhashi et al., 2015) . Interestingly, the A1075 allele of the ACE2 gene has been associated with increased mortality in male patients with acute coronary syndrome in the absence of, but not in the presence of βARB treatment, suggesting a pharmacogenetic effect linking ACE2 and βARBs (Palmer et al., 2008) . (RAS) . Classical RAS consists of angiotensin converting enzyme (ACE) breaking down Angiotensin (Ang)-I into Ang-II, both of which can bind to either the AT1 (angiotensin type 1) or the AT2 (angiotensin type 2) receptor. Non-classical RAS consists of ACE2 converting Ang-I into Ang-(1-9) and Ang-II into Ang-(1-7). Ang-(1-7) stimulates the Mas receptor. Bradykinin and [des-Arg9]-bradykinin are degraded by ACE and ACE2, respectively, into pharmacologically inactive peptides.

2.1. βARBs βARBs, mainly through β 1 receptor-mediated inhibition of the sympathetic nervous system, negatively regulate the release of renin from juxtaglomerular cells in the kidney and are thereby involved in RAS regulation. The contribution of renal sympathetic activity on the ACE2/Ang-(1-7)/Mas receptor pathway of the RAS has been investigated in disease models. Renal denervation decreases blood pressure, cardiac and renal fibrosis, cardiomyopathy, and oxidative stress. It upregulates cardiac and renal ACE2 protein expression in isoproterenol-induced cardiomyopathy (Q. Liu et al., 2015) , myocardial infarction (Feng et al., 2017) and hypertension models (W. Han et al., 2020; . In a recent study, renal denervation improved cardiac function, decreased fibrosis, and upregulated hypothalamic ACE2 mRNA and protein expression in a heart failure model (W. J. Chen et al., 2019) . In a rat model of type 2 diabetes mellitus with insulin resistance, renal denervation decreased plasma and renal tissue norepinephrine levels, improved vascular endothelial functions, and increased mRNA and protein expression of ACE2 in aortic endothelial cells. This effect was due to induction of autophagy via the "AMP-activated protein kinase" (AMPK) and "mammalian target of rapamycin" (mTOR) signaling pathways (Y. Wang, B. Rijal, et al., 2020) , suggesting that ACE2 expression in different regions can be regulated by sympathetic activity. Following treatment with the non-selective β adrenoreceptor agonist isoproterenol, both increased (Nadu, Ferreira, Reudelhuber, Bader, & Santos, 2008) and decreased (Syed et al., 2016) cardiac ACE2 expression have been reported in hypertrophy models. Similarly, while, isoproterenol downregulated cardiac ACE2 expression in a myopathy model (Q. Liu et al., 2015) , it upregulated cardiac ACE2 levels in a myocardial infarction model (Badae, El Naggar, & El Sayed, 2019) . A recent study in rat salivary glands reported isoproterenol-induced downregulation of ACE2 mRNA expression in the parotid, but not in the sublingual and submandibular glands (Cano et al., 2019) , suggesting that the effect of isoproterenol may vary between different tissues and disease models.

In spontaneously hypertensive (SH) rats, the βARB atenolol reduced the blood pressure to a similar extent as compared to hydralazine, a direct vasodilator, and olmesartan, an AT1-R blocker. However, atenolol and hydralazine showed no effect on ACE2 expression in both tissues (Igase, Strawn, Gallagher, Geary, & Ferrario, 2005) , whereas olmesartan caused marked upregulation of ACE2 in aortic tissue, but had no effect on the carotid artery (Igase, Strawn, Gallagher, Geary, & Ferrario, 2005) . Nebivolol, a βARB, did not decrease the blood pressure but reduced plasma renin concentration, cardiac Ang-II levels, oxidative stress, and fibrosis; cardiac ACE2 activity and mRNA levels remained essentially unchanged (Varagic et al., 2012) . However, in another study on SH rats, the βARB propranolol alone or in combination with the AT1-R blocker losartan or the ACE-Inh. captopril decreased the blood pressure and markedly reduced ACE2 mRNA expression in the aorta (Lezama-Martinez et al., 2018) . Of note, the βARB labetalol increased the maximal reaction rate and decreased the substrate specificity of ACE2 (Kulemina & Ostrov, 2011) , suggesting that at least some βARBs can interact directly with ACE2. βARBs have also been shown to decrease proinflammatory cytokines, including IL-1β, IL-6, TNFα, IFNγ (Deten, Volz, Holzl, Briest, & Zimmer, 2003; Doo et al., 2001; Hajighasemi & Mirshafiey, 2016; Matsumura et al., 2002) . Moreover, they reduce pulmonary edema (Rassler, 2012) , inhibit NLRP3 inflammasome (Wong et al., 2018) , and reduce the mortality and disease severity of acute respiratory distress syndrome (ARDS) (Al-Qadi & Kashyap, 2015; Noveanu et al., 2010) and chronic obstructive lung disease (COPD) (Nielsen, Pedersen, Sode, & Dahl, 2019) , suggesting that βARBs may have beneficial effects on COVID-19. In addition to βARBs, ⍺1-AR antagonists have recently been shown to prevent cytokine responses and to increase the survival after inflammatory stimuli in mouse models (Staedtke et al., 2018) . They also reduce morbidity and mortality in patients at risk for developing a cytokine storm syndrome (Vogelstein et al., 2020) . Briefly, the sympathetic nervous system activates the RAS through βARs, βARBs inhibit renin release, and renal denervation upregulates cardiac, renal and hypothalamic ACE2 expression in various disease models. In addition, decreased reactive oxygen species (ROS) production, increased endothelial nitric oxide synthase (NOS) expression and NO formation can lead to upregulation of ACE2 expression (W. Han et al., 2020; Varagic et al., 2012) . However, both increased and decreased ACE2 expression have been reported after application of the non-selective β adrenoreceptor agonist isoproterenol, and there is no consistent evidence that βARBs influence ACE2 expression or activity. In 221 hypertensive patients, no association between the use of βARBs and renal ACE2 gene expression was found (X. . In the context of COVID-19, a recent study with 880 COVID-19 patients reported that the use of βARBs was associated with a significantly better outcome (Pinto-Sietsma et al., 2020) .

There are few studies investigating the effects of calcium channel blockers (CCBs) on ACE2 regulation. Amlodipine (an L-type CCB) and cilnidipine (an L-and N-type CCB), not alone but in combination with valsartan, decreased the blood pressure but did not change aortic ACE2 mRNA expression (Takai, Jin, Aritomi, Niinuma, & Miyazaki, 2013) . In a mechanical stress model resulting in elevated ACE2 mRNA expression, Ang-II decreased ACE2 surface expression of pressurized human aortic endothelial cells, and nifedipine (an L-type CCB) reversed this effect (Iizuka, Kusunoki, Machida, & Hirafuji, 2009) . Felodipine (an L-type CCB) decreased blood pressure, fibrosis and TGF-β1 expression; but no changes in renal ACE2 mRNA expression were observed in ischemic or non-ischemic hypertensive rats (S. Bai, Huang, Chen, Wang, & Ding, 2013) . On the other hand, nimodipine treatment attenuated the reduction in brain ACE2 mRNA expression that occurs in ischemic brain tissue (Abdel-Fattah, Messiha, & Mansour, 2018) . Similarly, amlodipine increased renal ACE2 levels in hypertensive rats (Onat & ŞAhna, 2018) . In summary, data suggest that CCBs reverse reduced ACE2 expression in various disease models. Recently, in an analysis of 291 COVID-19 patients, the use of CCBs was not associated with increased disease severity or mortality rates (Fosbol et al., 2020) . In cell culture experiments, CCBs of the dihydropyridine class, amlodipine, felodipine and nifedipine, at high concentrations (10-500 μM), were reported to limit the growth of SARS-CoV-2 in epithelial kidney (Vero E6) and epithelial lung (Calu-3) cells (Straus, Bidon, Tang, Whittaker, & Daniel, 2020) .

The effects of most diuretic drugs on ACE2 are currently unknown. Among thiazide diuretics, hydrochlorothiazide increased cardiac ACE2 gene expression in normotensive but decreased it in hypertensive rats (Jessup, Brosnihan, Gallagher, Chappell, & Ferrario, 2008) . However, mineralocorticoid receptor blockers (MRBs) have been reported to regulate ACE2 activity and expression in various disease models. In macrophages from heart failure patients, the MRB spironolactone reduced oxidative stress and lipid peroxide formation, accompanied by a markedly upregulated ACE2 expression, whereas aldosterone significantly reduced it (Keidar et al., 2005) . Spironolactone also upregulated decreased ACE2 expression levels in aldosterone-treated cultured cardiomyocytes (Yamamuro et al., 2008) and kidney (Fukuda et al., 2011) , as well as in kidneys of rats with obstructive jaundice (Kong et al., 2019) , but not in human mesangial cells (Stoll, Yokota, Sanches Aragao, & Casarini, 2019) . Eplerenone, another MRB, did not consistently reverse decreased ACE2 levels in rats with experimental heart failure (Karram et al., 2005) and in the hearts of hypertensive rats (Takeda et al., 2007) , but completely reversed aldosterone-and high salt-induced down regulation of renal ACE2 expression (Bernardi et al., 2015) . Similarly, eplerenone reversed the aldosterone-induced, p47-mediated downregulation of ACE2 expression in mouse macrophages, heart and kidney (Keidar et al., 2005) . In addition, eplerenone was reported to inhibit ADAM17 activity in human monocytes (Satoh, Ishikawa, Minami, Akatsu, & Nakamura, 2006) , which should potentially promote cell surface ACE2 activity. In line with this, in a diabetic nephropathy model, improvement of kidney pathology by spironolactone was associated with decreased serum ACE2 levels (Dong et al., 2019) .

In summary, the majority of studies points to an increase in ACE2 expression after MRB treatment, mainly by counteracting aldosteroneinduced down regulation of ACE2. In addition, mitigation of the deleterious effects of obesity on the RAS, possibly reducing obesity-related COVID-19 complications (Feraco et al., 2013; Vecchiola et al., 2020) and direct anti-inflammatory and antiviral effects of MRBs, could be beneficial in the treatment of pulmonary COVID-19 complications (Cadegiani, Wambier, & Goren, 2020) . Importantly, MRBs such as spironolactone possess a significant anti-androgenic activity, which may be beneficial in the context of SARS-CoV-2 infection, by inhibiting the androgen-dependent expression of "Transmembrane protease, serine 2" (TMPRSS2), a transmembrane protease crucial for SARS-CoV-2 entry (Liaudet & Szabo, 2020) . In addition, potassium canrenoate (the active metabolite of spironolactone) results in concentration (0.1-10 μM)-dependent reductions of the binding of the SARS-CoV-2 spike protein to the ACE2 receptor (Carino et al., 2020) . Increased plasma aldosterone levels associated with disease severity in COVID-19 patients (Villard et al., 2020) suggest that MRBs may have beneficial effects in COVID-19. A recent study concluded that canrenone decreased allcause mortality and improved the clinical outcome in a small cohort of 30 COVID-19 patients with diseases ranging from moderate to severe (M. Vicenzi et al., 2020) . Another diuretic, furosemide, significantly decreased lipopolysaccharide-induced proinflammatory cytokine production in cell lines and potently inhibited IL-6 and TNF-α release (Z. , suggesting its potential use in hypercytokinemic conditions in COVID-19.

Blockers of AT1 receptors and ACE-Inhs. are the most commonly used drugs in the treatment of hypertension and cardiovascular diseases (Zolk et al., 2020) . As mentioned earlier, ACE2 antagonizes the effects of Ang II. At the cellular level, Ang-II, mainly by acting on AT1 receptors, downregulates the expression of ACE2 (Ferrario, Ahmad, & Groban, 2020) . Therefore, it can be expected that either the inhibition of Ang-II production by ACE-Inhs. or the blockade of AT1 receptors may lead to upregulation of ACE2 expression. In addition, activation of peroxisome proliferator-activated receptors (Harada et al., 2016; Horiuchi, Iwanami, & Mogi, 2012; Maquigussa et al., 2018; Michel, Foster, Brunner, & Liu, 2013; and sirtuin 1 (SIRT1) (Strycharz et al., 2018) by AT1-R blockers (ARBs), such as telmisartan, losartan and irbesartan, may further contribute to the upregulation of ACE2 expression (Goltsman et al., 2019; Gupte et al., 2008; W. Zhang et al., 2014) .

Detailed lists of experimental studies assessing the effects of ACE-Inhs. and ARBs on the expression or activity of ACE2 are provided in Tables 1 and 2, respectively. Not surprisingly, the majority of experimental studies supports the assumption that RAS inhibition upregulates ACE2 activity and expression, although there appear to be some differential responses between ARBs versus ACE-Inhs., between drugs belonging to the same group of drugs, and between different tissues and species. For example, in normotensive Lewis and hypertensive mRen2. Lewis male rats, the ARB losartan markedly increased ACE2 activity in the heart (Ferrario et al., 2005; Ferrario et al., 2005) ; a similar increase in cardiac ACE2 activity was reported for the ARB eprosartan in rats with heart failure (Karram et al., 2005) . The ACE-Inh. lisinopril, however, either failed to increase cardiac ACE2 activity (Lewis rats) or stimulated it to a lesser extent than losartan (in murine Ren2 renin transgenic rats), despite similar reductions in blood pressure (Ferrario, Jessup, Chappell, et al., 2005; Ferrario, Jessup, Gallagher, et al., 2005; Jessup et al., 2006) . In the kidneys of both strains, losartan and lisinopril increased ACE2 activity (Ferrario, Jessup, Chappell, et al., 2005; Ferrario, Jessup, Gallagher, et al., 2005; Jessup et al., 2006) , although to a lesser degree compared to the heart. On the other hand, it was found that the ACE-Inh. ramipril reduced cardiac ACE2 activity in a rat model of kidney injury (L. Burchill et al., 2008) .

Interestingly, a recent study reported that renal ACE2 levels were decreased and pulmonary ACE2 levels remained unchanged in ACE knockout mice or in mice treated with ACE-Inhs. or ARBs (Jan Wysocki, Lores, Ye, Soler, & Batlle, 2020) . In another recent study, treatments with the ACE-Inh. enalapril or the ARB losartan did not affect ACE2 mRNA expression in lung, ileum, kidney, and heart of normotensive healthy C57BL/6J mice (Congqing Wu et al., 2020) . Similarly, treatment with the ACE-Inh. lisinopril (100 nM) did not alter ACE2 expression in A549 lung cancer cells (Bartova, Legartova, Krejci, & Arcidiacono, 2020) . In another recent study on human alveolar adenocarcinoma (A549) and lung cancer (Calu-3) cell lines, Ang-I (10-1000 nM) and Ang-II (1-100 nM) did not alter ACE2 expression. Treatment with ARBs, such as losartan and valsartan, and ACE-Inhs., such as lisinopril and captopril, did not affect ACE2 expression in these pulmonary cells (Baba et al., 2020) .

The results of clinical studies investigating the effects of therapeutic concentrations of ARBs and ACE-Inhs. on ACE2 levels in biopsy, plasma and urine samples are provided in Table 3 . The majority of these studies reports no effect of ACE-Inhs. and ARBs on samples obtained from patients with cardiovascular diseases. In a recent study on kidney biopsies of diabetic patients, the use of ARBs and ACE-Inhs. did not change ACE2 mRNA expression (R. E. Gilbert et al., 2020) . However, in atrial biopsies from patients with cardiovascular diseases, treatment with ARBs and ACE-Inhs. significantly increased ACE2 mRNA expression (Lebek et al., 2020) .

Concerning plasma ACE2 levels, a recent study with 2,022 heart failure patients reported that neither the use of an ACE-Inh. nor of an ARB was associated with higher plasma ACE2 concentrations (Sama et al., 2020) . In clinical studies involving patients with heart failure (Chirinos et al., 2020; Epelman et al., 2009; Sama et al., 2020) , atrial fibrillation, (Walters et al., 2017) , hypertension (Kuznetsova & Cauwenberghs, 2020) , aortic stenosis (Ramchand et al., 2020) , and coronary artery disease (Ramchand, Patel, Srivastava, Farouque, & Burrell, 2018) , plasma ACE2 protein levels or ACE2 activities were not higher among patients who were taking ACE-Inhs. or ARBs than among untreated patients. In addition, in patients with genetic variants of the ACE gene, no association of genetically predicted serum ACE levels with lung ACE2 and TMPRSS2 expression or with plasma levels of ACE2 was found (Gill et al., 2020) . In a recent study, serum ACE2 levels of 1,452 individuals on ACE-Inh. or ARB treatment remained unaffected compared to those not using these medications (Emilsson et al., 2020) . Similarly, another recent study reported that plasma ACE2 activity remained unaltered in patients treated with ACE-Inhs. and ARBs (Kintscher et al., 2020) . However, this study reported that plasma ACE2 activity was significantly increased in a small cohort of COVID-19 patients using ACE-Inhs. In line with this finding, ACE-Inh. and ARB treatment was associated with high plasma ACE2 levels in a large cohort of patients with atrial fibrillation (Wallentin et al., 2020) .

In earlier human studies measuring plasma Ang-(1-7) levels as surrogate for ACE2 activity, while acute administration of ACE-Inhs. did not alter Ang-(1-7) levels (Campbell, Zeitz, Esler, & Horowitz, 2004; Luque et al., 1996) , chronic use (6 months) of ACE-Inhs. increased Ang-(1-7) levels (Luque et al., 1996) . Importantly, plasma ACE2 activity may not represent enzymatic activity at the tissue level, as Ang-II infusion into mice decreases myocardial ACE2 protein level and activity but increases plasma ACE2 activity (Patel et al., 2014) . Interestingly, the Cardiac ACE2 mRNA expression and ACE2 activity increased by myocardial ischemia. Ramipril did not cause any change. Burrell et al. (2005) Lisinopril/ ACE-Inh. Lewis rats/ Heart Decrease in plasma Ang II, increase in plasma Ang 1-7 and ACE2 mRNA, but not cardiac ACE2 Activity Ferrario, Jessup, Chappell, et al. (2005) Lisinopril/ACE-Inh. Losartan/ARB Lewis rats/ Kidney Lisinopril or Losartan treatment were both associated with increases in ACE2 activity but used in combination, did not produce this effect. Ferrario, Jessup, Gallagher, et al. (2005) Lisinopril/ACE-Inh. Lewis and hypertensive mRen2.Lewis rats Increased renal ACE2 mRNA expression in hypertensive but not in normotensive rats. Chappel and Ferrario (2006) Enalapril/ACE-Inh. Sprague Dawley rats/ Coronary artery ligation in heart Increased plasma and cardiac ACE2 activity, and cardiac ACE2 mRNA levels 8 weeks post-surgery Ocaranza et al. (2006) Lisinopril/ACE-Inh. Transgenic Ren2 rats/ Heart and kidney Decrease in plasma Ang II, increase in plasma Ang 1-7, cardiac and renal ACE2 mRNA and activity Jessup et al. (2006) Lisinopril/ ACE-Inh. Lewis rats/ Kidney No change in kidney ACE2 mRNA, but increased ACE2 activity Ferrario, Jessup, Gallagher, et al. (2005) Burrell, Gayed, Griggs, Patel, & Velkoska (2017) antihypertensive effects of captopril (X. Fan et al., 2007) , benazepril (Q. Chen et al., 2011; , and imidapril (Y. Y. Chen et al., 2016) are reportedly associated with polymorphisms or variations in the ACE2 gene in a gender-specific manner; however serum ACE2 levels have not been reported in these studies. In a longitudinal cohort study involving Japanese patients with hypertension, urinary ACE2 levels were higher among patients who received long-term treatment with the ARB olmesartan than among untreated control patients. However, this association was not observed with the ACE inhibitor enalapril or with other ARBs, such as losartan, candesartan, valsartan, and telmisartan (Furuhashi et al., 2015) . Correlation analysis of cardiac tissue samples from 11 patients with heart failure did not show any significant relation between angiotensinase activity and prior use of ACE-Inhs. (Zisman et al., 2003) . Notably, ACE2 mRNA expression remained unchanged in bronchial epithelial cells from a small cohort of patients with COPD using ACE-Inhs. (Higham & Singh, 2020) . In a small cohort of 11 patients with kidney disease, a statistically significant increase in ACE2 expression with use of ACE-Inhs. or ARBs was detected in renal epithelial and endothelial cells, but the underlying diseases confounded the association (Subramanian et al., 2020) . In another study, ACE2 expression slightly, but significantly decreased in nasal cilia of patients taking ACE-Inhs. and remained unchanged in patients using ARBs (Ivan T . In 221 hypertensive patients, no association between ACE-Inhs. or ARBs and renal ACE2 gene expression was found (X. . In addition, in kidney biopsies from 49 diabetic patients, treatment with ARBs and ACE-Inhs. did not change ACE2 mRNA expression (R. E. Gilbert et al., 2020) . A recent gene expression analysis of 1,051 lung tissue samples indicated that the use of ACE-Inhs. was associated with lower expression of ACE2 and of the SARS-Cov-2 activator TMPRSS2, while the use of ARBs was not associated with an increased expression of these genes (Milne, Yang, Timens, Bosse, & Sin, 2020) . However, in 62 patients undergoing coronary artery bypass grafting, treatment with ARBs and ACE-Inhs. was independently associated with an increased myocardial ACE2 mRNA expression (Lebek et al., 2020) . Importantly, in sino-nasal biopsies from patients, treatment with ACE-Inhs. or ARBs did not increase ACE2 expression in the cilia of the upper respiratory tract (I. T. . Altogether, these clinical studies strongly suggest that treatment with ACE-Inhs. and ARBs is not associated with increased ACE2 expression.

In a propensity analysis of 12,594 patients tested for COVID-19, there was no association between any single medication class, including ACE-Inhs., ARBs, CCBs, βARBs, and thiazide diuretics, and an increased likelihood of a positive test. Moreover, none of these medications was associated with an increased risk of severe illness among patients who tested positive (Reynolds et al., 2020) . In a population based retrospective study of 34,936-hypertensive adults, the use of antihypertensive drugs, including diuretics, CCBs, βARBs, ACE-Inhs. and ARBs, did not alter the risk of COVID-19 (Vila-Corcoles et al., 2020) . Similarly, in a recent study analyzing 6,272 COVID-19 patients, no association between the use of ACE-Inhs. and ARBs (as well as CCBs and βARBs), and COVID-19 risk was found (Mancia, Rea, Ludergnani, Apolone, & Corrao, 2020) . Equally, another propensity analysis of 18,472 patients tested for COVID-19 did not reveal any association between ACE-Inh. or ARB use and COVID-19 test positivity . In a retrospective study with 4,480 COVID-19 patients, prior use of ACE-Inhs. and ARBs was not significantly associated with COVID-19 diagnosis among patients with hypertension or with severe disease conditions (Fosbol et al., 2020) . In a large population study, patients using ARBs or CCBs had a lower risk of COVID-19 (J. Kim et al., 2020) . Other studies also found no association between the use of ACE-Inhs., ARBs and an increased risk of testing positive for SARS-CoV-2 or a more severe outcome De Spiegeleer et al., 2020; Son, Seo, & Yang, 2020) . Instead, the use of ARB and ACE-Inhs. was associated with no risk (Dublin et al., 2020; Raisi-Estabragh et al., 2020) or a reduced risk of COVID-19, as determined by an 8.3 million cohort study (Hippisley-Cox et al., 2020) .

In line with these findings, the clinical outcome of 136 diabetic and hypertensive COVID-19 patients using ACE-Inhs. or ARBs was not different from that of patients who do not use these drugs (Y. Chen, D. Yang, et al., 2020) . In a study with 1,200 COVID-19 patients, no evidence for increased disease severity was found in hospitalized patients on chronic treatment with ACE-Inhs. or ARBs (Bean et al., 2020) . Similarly, in 50 high-risk aged COVID-19 patients with cardiovascular disease, the ACE-Inh. ramipril had no impact on the incidence or the severity of the disease (Amat- Santos et al., 2020) . In another recent study with 880 COVID-19 patients, no evidence for an adverse outcome was found in severely affected COVID-19 patients that had used ARBs prior to admission (Pinto-Sietsma et al., 2020) . In 2,263 hypertensive Increase in plasma Ang II, Ang 1-7 and ACE2 mRNA 28 days post surgery Ishiyama et al. (2004) Eprosartan/ARB Male Wistar rats/ Aortocaval fistula induced heart failure model Heart failure caused decreased cardiac ACE2 expression and enzyme activity was restored by eprosartan Karram et al. (2005) Losartan/ ARB Lewis rats/ Heart Increase in plasma Ang II, Ang 1-7 levels, ACE2 mRNA and cardiac ACE2 activity Ferrario, Jessup, Chappell, et al. (2005) Olmesartan/ ARB Spontaneously hypertensive rats/ Aorta Markedly increased aortic ACE2 immunostaining and mRNA expression. But no effect on carotid artery Igase et al. (2005) Losartan/ ARB Transgenic Ren2 rats/ Heart and kidney Increase in plasma Ang II, Ang 1-7, cardiac and renal ACE2 mRNA and activity Jessup et al. (2006) Losartan/ ARB Lewis and hypertensive mRen2.Lewis rats Increased renal ACE2 mRNA expression in hypertensive but not in normotensive rats. Chappel and Ferrario (2006) Olmesartan ACE2 expression was unchanged in control rats by either dose of losartan. Animals exposed to cigarette smoke had reduced ACE2, which losartan treatment restored S. X. Han et al. (2010) Losartan/ ARB Male C57BL/6 mice/ Fructose diet Losartan alone increased renal ACE2 protein expression but no effect on ACE2 activity; also reversed the increasing effect of fructose COVID-19 patients, the use of ACE-Inhs. or ARBs was not associated with an altered risk of hospitalization or mortality. In analyses stratified by insurance group, the use of ACE-Inhs. lowered the risk of hospitalization by nearly 40% in the Medicare group, a phenomenon not observed in commercially insured patients (Khera et al., 2020) . Similarly, in a casepopulation study of 1,139 COVID-19 patients, the risk of hospitalization among users of ACE-Inhs. or ARBs was not different from that of users of other antihypertensive drugs; and no increased risk of hospitalization was associated with the use of either ACE-Inhs. or ARBs (de Abajo et al., 2020). Equally, in 543 hypertensive COVID-19 patients, no association was found between disease severity and treatment with ARBs and ACE-Inhs. (Bravi et al., 2020) . In a rather large multinational cohort, no clinically significantly increased risk of COVID-19 diagnosis or hospitalization was found in patients using ACE-Inhs. or ARBs . In addition, the use of ACE-Inhs. and ARBs did not affect mortality rates in small cohorts of COVID-19 patients (Amat- Santos et al., 2020; Iaccarino et al., 2020; Inciardi et al., 2020; Tedeschi et al., 2020) . Another recent study of 5,179 COVID-19 patients in Korea concluded that prior use of ACE-Inhs. and ARBs was not independently associated with increased mortality rates (S. Y. Jung, Choi, You, & Kim, 2020). In small cohorts of hypertensive COVID-19 patients, the use of ACE-Inhs. and ARBs did not significantly change the clinical course, disease severity and mortality rates (Z. J. Li, Wang, Chen, Zhang, & Deng, 2020; Sardu et al., 2020; Jiuyang Xu et al., 2020) . A retrograde analysis of 2,700 intensive care patients with severe sepsis and septic shock unrelated to COVID-19 indicates no difference in mortality rates between users of ACE-Inhs. or ARBs and non-users within the subgroup of patients with respiratory infections (Sunden-Cullberg, 2020). Also, previous treatment with ACE-Inhs. or ARBs had no effect on mortality, heart failure, requirement for hospitalization, or ICU No association was found between ACE-Inh. and ARB use and ACE2 levels.

Epelman et al. (2009) ACE-Inh. and ARB undefined 859 patients with type 1 diabetes and 204 healthy control subjects.

Mild increase in serum ACE2 was increased~10 to 20% (higher in women) In diabetics using ACEIs, No association was found between ARB usage and ACE2 levels.

Soro-Paavonen et al. 2020; Z. Wang, D. Zhang, et al., 2020) . Altogether, these results indicate that the use of ACE-Inhs. or ARBs neither increases the COVID-19 risk, nor disease severity nor mortality rates.

In line with these findings, in 188 COVID-19 patients with hypertension, the use of ACE-Inhs. and ARBs was associated with a lower risk of all-cause mortality, compared with non-users (P. . In small cohorts of hypertensive COVID-19 patients, the use of ACE-Inhs. and ARBs significantly improved disease severity, immune response, laboratory findings and viral load (J. Meng et al., 2020; Pan et al., 2018; G. Yang et al., 2020) . In 157 critically ill elderly COVID-19 patients, medication with ACE-Inhs. was associated with lower mortality rates (C. Jung et al., 2020) . Similarly, the use of ACE-Inhs. and ARBs was associated with a reduced risk of COVID-19-related hospitalization for diabetic patients (de Abajo et al., 2020) . COVID-19 patients continuing to receive ACE Inhs. or ARBs had a lower risk of mortality compared with those who discontinued at the time of hospitalization (Cannata et al., 2020; Lam et al., 2020) . In 892 hypertensive COVID-19 patients, the use of ACE-Inhs. and ARBs was associated with significantly improved outcome and disease severity compared with non-use or the use of other antihypertensive drugs (H. K. . In 249 hypertensive COVID-19 patients, medication with ACE-Inhs. significantly reduced the risk of severe disease and was associated with milder lung infiltrations, milder disease progress and shorter hospitalizations (Şenkal et al., 2020) . Furthermore, recent additional studies also report that treatment with ARBs and ACE-Inhs. is associated with reduced disease severity and decreased mortality rates in COVID-19 patients (Adrish et al., 2020; C. H. K. Choi et al., 2020; Genet et al., 2020; Matsuzawa et al., 2020; Megaly & Glogoza, 2020; X. Meng et al., 2020; Negreira-Caamaño et al., 2020; Palazzuoli et al., 2020; Yahyavi et al., 2020; . Another recent study concluded that among patients with influenza or pneumonia, treatment with ARBs and ACE-Inhs. did not increase the risk of admission to the intensive care unit, but reduced the mortality . Briefly, all of the above results suggest that the use of ACE-Inhs. and ARBs does not increase disease pathology; on the contrary, these medications may have some beneficial effects on the clinical outcome of COVID-19.

However, recently some studies have appeared pointing to the opposite: in a retrospective cohort study of 268 COVID-19 patients, the long-term use of ACE-Inhs. and ARBs was independently associated with a higher risk of severe COVID-19 and a poor outcome (Liabeuf et al., 2020) . In a large cohort of patients taking ACE-Inhs. or ARBs, the use of ACE-Inhs. was associated with increased rates of S. Aerus and gram-negative infections, while herpes zoster was more commonly associated with ARBs (Bidulka et al., 2020) . In addition, the use of ACE-Inhs. and ARBs was associated with a higher risk of in-hospital mortality in 74 hypertensive patients with COVID-19 pneumonia (Selcuk et al., 2020) . In 44 patients with severe COVID-19, the use of ACE-Inhs. and ARBs was associated with an increased risk of acute kidney injury, and an increase in urea nitrogen associated with these drugs was predictive of the development of acute respiratory failure (Oussalah et al., 2020) . There is a report of four COVID-19 patients, in whom ACE-Inhs. or ARBs had to be stopped due to acute kidney injury (Chenna et al., 2020) . In addition, the use of ACE-Inhs. was found to be associated with an increased incidence and higher mortality rates in 466 patients infected with human Coronavirus NL63 (Krvavac et al., 2020) .

Despite initial concerns, RAS inhibition was suggested to have beneficial effects for COVID-19 patients. The role of the RAS in the pathogenesis of acute lung injury appears to center around elevated Ang-II signaling through AT1 receptors. In small cohorts of COVID-19 (Y. and H7N9 (F. Huang et al., 2014) infected patients, as well as children with respiratory syncytial virus (Gu et al., 2016) , serum Ang-II levels were significantly higher in infected individuals than in non-infected individuals and were associated with viral load and lung injury. A retrospective review of 539 patients with viral pneumonia indicates that continuing in-hospital use of ACE-Inhs. or ARBs reduces the risk of pneumonia and mortality (Henry et al., 2018) . Furthermore, in a meta-analysis of 37 studies, both ACE-Inhs. and ARBs were associated with a decrease in pneumonia-related mortality (Caldeira, Alarcao, Vaz-Carneiro, & Costa, 2012) . Interestingly, patient populations that may benefit most were found to be those with a history of stroke and Asian patients. A retrospective cohort study with hospitalized pneumonia patients reported that prior and inpatient use of ACE-Inhs. and ARBs was associated with decreased mortality rates (Mortensen et al., 2012) . Similarly, decreased mortality and better survival rates were reported in patients with ARDS taking ACE-Inhs. and ARBs, compared to those not using these medications (J. . Analysis of a randomized control trial in patients with acute respiratory failure suggested that treatment with ACE-Inhs. and ARBs at discharge following an episode of acute respiratory failure was associated with a significant (44%) reduction in one-year mortality (Noveanu et al., 2010) . More recently, preadmission use of ACE-Inhs. or ARBs was reported to be associated with a decreased risk of total hospital mortality (Hsieh, How, Hsieh, & Chen, 2020) . In addition, losartan demonstrated beneficial effects in animal models of ventilatorassociated lung injury (C. Chen et al., 2014; Jerng et al., 2007; S. Yao, Feng, Wu, Li, & Wang, 2008) . Similarly, blockade of AT1 receptors attenuates lung injury in mice that have been administered the spike glycoprotein of SARS-CoV . ARBs delay the onset of ARDS and decrease lung injury in rats challenged by Bordetella bronchiseptica (Raiden et al., 2002) or lipopolysaccharide (Wosten-van Asperen et al., 2011) . Moreover, in a recent large population study, the use of ACE-Inhs. and ARBs was associated with either no effect on the incidence of influenza or a lower incidence, depending on the duration of use (Chung, Providencia, & Sofat, 2020) . In summary, clinical and preclinical studies indicate that treatment with ACE-Inhs. or ARBs has beneficial effects in patients with ARDS, irrespective whether it is COVID-19 related or not.

A major complication of SARS-CoV-2 infection is the development of severe lung disease leading to pulmonary fibrosis. In the adult lung, the major source of ACE2 are the normally quiescent alveolar epithelial type II pneumocytes that, during lung fibrosis, proliferate actively and downregulate ACE2 expression (H. P. Jia et al., 2005; Uhal et al., 2013) . In these cells, ACE2 expression can be further decreased by SARS-CoV-2 induced downregulation. Thus, it is plausible that a diminished ACE2/ Ang-(1-7)/MasR axis and an unbalanced increase of the ACE/ Ang-II/ AT1 receptor pathway can lead to pulmonary vasoconstriction. Together with inflammation (promoting the production of proinflammatory cytokines, such as IL-6, IL-8, TGF-β, and TNF-α by macrophages), oxidative organ damage, and increased collagen production, this can promote acute lung injury and subsequent fibrosis (Delpino & Quarleri, 2020; Wigén, Löfdahl, Bjermer, Elowsson-Rendin, & Westergren-Thorsson, 2020) .

ACE2 decreases Ang-II levels by generating Ang-(1-7), which acts on the MasR and exerts vasodilatory, anti-inflammatory, antioxidative, and anti-fibrotic actions (J. Guo, Huang, Lin, & Lv, 2020) . In patients with ARDS, a higher ratio of Ang-(1-7) to Ang-I among survivors was observed, compared to non-survivors (Reddy et al., 2019) . In addition, treatment with Ang-(1-7) decreases lung injury and attenuates ARDS in rats with low Ang-(1-7) levels (Wosten-van Asperen et al., 2011), suggesting that the counter-regulation exerted by the ACE2/Ang-(1-7)/MasR axis may benefit patients with ARDS. In mice, losartan reduced mortality by blunting Ang-II-associated increases in soluble epoxide hydrolase, a promoter of lung injury (Tao et al., 2018) . Activation of the Ang-(1-7)/ACE2/MasR axis inhibits pulmonary fibrosis (Meng et al., 2014; Meng et al., 2015) and protects from thrombosis (R. A. Fraga- . Treatment with soluble ACE2 has been shown to reduce Ang-II levels and to increase Ang-(1-7) levels in a clinical trial of patients with ARDS (A. Khan et al., 2017) . In line with these findings, recombinant soluble ACE2 attenuates the inflammatory response, increases oxygenation and protects from lung injury in animal models of ARDS P. Yang et al., 2014; H. Zhang & Baker, 2017; Zou et al., 2014) . Of note, meta-analyses of earlier results reported that ACE insertion/deletion polymorphism might contribute to disease mortality (Matsuda, Kishi, Jacob, Aziz, & Wang, 2012) and the susceptibility for ARDS . On the other hand, an earlier study could not find any association between ACE2 gene polymorphism and disease severity in ARDS patients (Chiu et al., 2004) .

Altogether, a recent meta-analysis of clinical studies on ACE-Inhs. and ARBs concluded that high-certainty evidence suggests that ACE-Inh. or ARB use is not associated with more severe COVID-19 disease; and moderate-certainty evidence suggests no association between the use of these medications and positive SARS-CoV-2 test results among symptomatic patients. Whether these medications increase the risk for mild or asymptomatic disease or are beneficial in COVID-19 treatment remains uncertain (Kansagara, Mackey, & Vela, 2020) .

Renin inhibitors, such as aliskiren, inhibit the first and rate-limiting step of the RAS, namely the conversion of angiotensinogen to angiotensin I; they are used primarily for the treatment of essential hypertension. Aliskiren attenuated the blood pressure without affecting glucose metabolism, insulin resistance, and pancreatic β-cell mass, and did not alter pancreatic ACE2 protein expression in high fatinduced obese mice (Frantz, Crespo-Mascarenhas, Barreto-Vianna, Aguila, & Mandarim-de-Lacerda, 2013) . In the offspring of rats maternally exposed to high fructose intake, aliskiren prevented hypertension and increased renal ACE2 expression in females, but not in males (Hsu et al., 2016) . In another study, aliskiren significantly reduced gingival inflammation, excessive wound healing processes, and periodontal bone loss in diabetic rats with periodontal disease (Oliveira et al., 2019) , accompanied by a marked downregulation of gingival ACE2 gene expression. In non-obese diabetic mice, aliskiren decreased blood pressure and serum renin activity, raised renal ACE2 gene but not protein expression and increased ACE2 activity (Riera et al., 2016) . In a renal transplantation model, aliskiren decreased not only serum Ang-II, but also levels of the renoprotective Ang-(1-7), and decreased serum ACE2 activity (Rusai et al., 2011) .

Commonly used cardiac or cardiotonic glycosides, such as digoxin and digitoxin, act mainly by inhibiting cardiac Na-K-ATPase. They are employed for the treatment of congestive heart failure and cardiac arrhythmias and have not been reported to affect ACE2 transcription or activity. Interestingly, cardiotonic glycosides, such as ouabain and the vertebrate-derived analogue bufalin, at low concentrations and independently of Na-K-ATPase inhibition, prevent the fusion and interfere with clathrin-mediated uptake of Middle East respiratory syndrome (MERS)-CoV, CoV-MHV, and CoV-FIP in cell lines through the α1-subunit of the Na-K-ATPase-mediated Src signaling pathway (Amarelle & Lecuona, 2018; Burkard et al., 2015) . Similarly, cardiotonic glycosides, including digoxin, digitoxin, oleandrin, and ouabain, inhibited the replication of CoV-TEG, but not CoV-MHV, and protected from virus-induced apoptosis and cytopathic effects in ST cells (C. W. Yang et al., 2017) through the phosphoinositide 3-kinasephosphoinositide-dependent kinase-1 (PI3K-PDK1) signaling pathway (C. W. Yang, Chang, Lee, Hsu, & Lee, 2018) . Digitoxin, ouabain, and bufalin, at low μM concentrations, also reportedly inhibit the replication of the "porcine reproductive and respiratory syndrome virus", which belongs to the order Nidovirales, remotely related to SARS-CoV (Karuppannan, Wu, Qiang, Chu, & Kwang, 2012) . Recently, digitoxin (Ko, Jeon, Ryu, & Kim, 2020) , digoxin and ouabain were shown to have antiviral activity against SARS-CoV-2 with respective IC 50 values of 43 nM and 24 nM. They were also reported to inhibit viral mRNA expression, copy number, and viral protein expression in Vero cells . In addition, digitoxin reportedly inhibits an influenza virus-induced cytokine storm and reduces pulmonary levels of proinflammatory cytokines in rodent models (Pollard, JC, & Pollard, 2020 ).

Commonly used anticoagulant and thrombolytic medications have not been reported to interact with the activity or expression of ACE2. Thrombolytic effects of ACE2 activation have been demonstrated (R. A. Fraga- Santos et al., 2018) . Similarly, Ang-(1-7) produced by ACE2 shows antithrombotic effects in animal models (Rodrigo Araujo Fraga-Silva et al., 2011) . While pharmacological activation of ACE2 by xanthene (XNT) reduces thrombus formation in the vena cava of hypertensive rats, ACE2 inhibition by DX600 promotes thrombosis (R. A. Fraga- . In addition, XNT diminishes platelet attachment to damaged blood vessels, reduces thrombus size, and prolongs the time to complete occlusion of blood vessels in mice. Therefore, a decrease in antithrombotic ACE2 activity is associated with an increase in thromboses in hypertensive rats. Under pathological conditions, AT1 receptor activation by Ang-II has been shown to induce deleterious effects, such as vasoconstriction, oxidative stress, platelet aggregation and exacerbated thrombus formation (Celi, Cianchetti, Dell'Omo, & Pedrinelli, 2010; Santos et al., 2018) . Therefore, a decreased vascular ACE2/Ang-(1-7)/Mas receptor pathway and unopposed ACE/ Ang II/AT1 activity during viral invasion can promote coagulation and thrombo-embolic events. Furthermore, increased bradykinin levels, due to ACE2 deficiency, may promote thrombus formation, since knockout of the bradykinin receptor B2 can prevent thrombus formation in a murine model (Shariat-Madar et al., 2006) .

Sepsis-induced coagulopathy, increased risk of thromboembolism and disseminated intravascular coagulation in COVID-19 patients (Thachil, 2020; Whyte, Morrow, Mitchell, Chowdary, & Mutch, 2020) have prompted the use of anticoagulants, mainly low-molecular weight heparins. Heparin, in addition to its anticoagulant effects, can also abrogate the adverse effects of the ACE/Ang II/AT1 axis in cardiomyocytes (Akimoto et al., 1996) , mesenteric arteries (Xie-Zukauskas, Das, Short, Gutkind, & Ray, 2013) , and other vascular structures (Dilley & Nataatmadja, 1998; J. S. Park, Kim, Won, Koh, & Kim, 1996) and counteract Ang-II-induced aldosterone stimulation (Azukizawa, Iwasaki, Kigoshi, Uchida, & Morimoto, 1988) . In addition, heparin exhibits antiviral properties, mainly due to its structural analogy with heparan sulfate (HS), a highly negatively charged linear polysaccharide attached to membrane proteins and extracellular matrix proteoglycans. It has been reported that culture-adapted HCoV-OC43 (de Haan et al., 2008) , mouse CoV (de Haan et al., 2005; Watanabe, Sawicki, & Taguchi, 2007) , porcine CoV (Huan et al., 2015) , and avian CoV (Madu et al., 2007) employ heparan-sulfate proteoglycans for adhesion or entry to susceptible cells. In addition, HCoV-NL63 (Milewska et al., 2014) , SARS-CoV (Lang et al., 2011; E. Vicenzi et al., 2004) , and SARS-CoV-2 use ACE2 as an entry receptor and utilize heparan sulfate proteoglycans as attachment receptors, and heparin acts as competitor preventing the binding of the spike protein to the host cell, thereby reducing the infection rate and mortality. Treatment with heparin lyases, which degrade cell surface heparan sulfates, drastically reduces the binding of SARS-CoV-2 spike protein to the cell surface . In a recent study, it has been shown that heparin forms 1:1 complexes with the receptor-binding domain of the S1 protein and disrupts its binding to ACE2 (Y. Yang, Du, & Kaltashov, 2020) . In the context of SARS-CoV-2, a growing body of evidence suggests that SARS-CoV-2 can bind the glycosaminoglycans HS and unfractionated heparin (UFH), dependent on their level of sulphation (W. Hao et al., 2020; Mycroft-West et al., 2020; Tree et al., 2020) . Initial binding to heparan sulphates was suggested to trigger conformational changes Mycroft-West et al., 2020) and to keep the spike protein within an 'open' conformation allowing for downstream binding and processing of ACE2 and host cell proteases, respectively (W. Hao et al., 2020) . It was proposed that while the receptor-binding domain of the SARS-CoV-2 spike (S) protein confers sequence specificity for heparan sulphates expressed by target cells, an additional HS binding site in the S1/S2 proteolytic cleavage site enhances the avidity of binding to ACE2 (L. . Recent studies suggest that multiple heparin and heparan sulfate binding sites are present on the SARS-CoV-2 spike protein; one at the S1/S2 furin cleavage site, and others at the S2 protein and within the receptor binding domain of S1 . UFH and two low molecular weight heparins (dalteparin and enoxaparin) inhibited SARS-CoV-2 spike protein binding in RT4 carcinoma , Vero (Mycroft-West et al., 2020; Tree et al., 2020) and HEK293T cell lines (Tandon et al., 2020) . Importantly, the IC 50 values for inhibition of S protein binding to ACE2 expressing cell lines for UFH, dalteparin and enoxaparin were 0.03 U/ml, 0.5 U/ml, and 0.07 U/ ml, respectively, which are below their target prophylactic and therapeutic serum concentrations (Kwon et al., 2020; Tree et al., 2020) . Furthermore, non-anticoagulant complex sulphated polysaccharides (fucoidans), such as RPI-27 (EC 50 = 83 nM) and trisulfated heparin (EC 50 = 5 μM), potently inhibited SARS-CoV-2 infection in Vero cells (Kwon et al., 2020) .

Recently, it was reported that the heparan sulfate mimetic pixatimod, a clinical-stage synthetic sulfated compound, binds directly to the S1 protein of SARS-CoV-2. It also inhibits its interaction with ACE2 and reduces viral infection in Vero E6 cells (Guimond et al., 2020) . In addition to their interaction with the spike protein, the cell surface heparan sulfate proteoglycans (HSPGs) mediate SARS-CoV-2 endocytosis. Heparin and drugs that target this HSPG-dependent endocytosis, such as mitoxantrone and sunitinib, potently inhibit SARS-CoV-2 entry (Q. . Similarly, HSPGs modified by the 3-O-sulfotransferase isoform-3 preferentially increase spike glycoprotein-mediated cell-to-cell fusion. Competition with either fondaparinux, a 3-O-sulfated HS-binding oligopeptide, or a small synthetic non-sugar molecule blocked spike protein-mediated cell-to-cell fusion. Finally, the synthetic sulfated molecule inhibited (0.1-1 μM) fusion of pseudo SARS-CoV-2 with HEK-293T cells . Interestingly, HS-modifying bacteria in human microbial communities may regulate viral adhesion; and loss of these commensals may predispose individuals to infection (Martino et al., 2020) .

Furthermore, heparin catalyzes the conformational change of serpins (serine protease inhibitors), such as antithrombin III, to accelerate inactivation of proteases, including factor Xa, trypsin (Huntington, 2005) , and cathepsin L (Higgins, Fox, Kowalski, Nielsen, & Worrall, 2010) , which are involved in the entry and replication of SARS-CoV (L. Du et al., 2007; Millet & Whittaker, 2015) . In summary, antiviral, anti RAS, and anti-aldosterone effects, coupled with endothelial protective, antioxidative (Thachil, 2020) and antinflammatory (Costanzo et al., 2020) properties, are useful features of heparin, besides its anticoagulant effects, in the treatment of ARDS and prevention of COVID-19 related thromboembolic events (Whyte, Morrow, Mitchell, Chowdary, & Mutch, 2020) . Potential beneficial effects of heparin in the treatment of COVID-19 are illustrated in Fig. 2 . Of note, while heparin does not affect ADAM17 expression (H. Cui et al., 2011) , aspirin, although at relatively high concentrations, promotes ADAM17-mediated shedding (Aktas et al., 2005) . Finally, aspirin, another anticoagulant, has been shown to activate SIRT1 (Aşcı et al., 2016; Y. R. Jung et al., 2015; Kamble, Selvarajan, Aluganti Narasimhulu, Nandave, & Parthasarathy, 2013) , which is expressed next to the promotor region of the ACE2 gene; hence its activation is potentially associated with ACE2 upregulation (Clarke, Belyaev, Lambert, & Turner, 2014) . In a recent study of 98 COVID-19 patients, the use of aspirin was associated with a decrease in mechanical ventilation, in intensive care unit admission, and in in-hospital mortality . A list of the effects of cardiovascular drugs on the activity and expression of ACE2 is provided in Table 4 .

Thiazolidinediones, such as pioglitazone and rosiglitazone, agonists of peroxisome proliferator-activated receptor gamma, are used in the treatment of type 2 diabetes mellitus (T2DM) as insulin sensitizers with anti-inflammatory and anti-atherosclerotic effects. In rats with steatohepatitis induced by high fat diet, pioglitazone increased serum ACE2 levels and ACE2 mRNA expression in the liver (W. Zhang, C. Li et al., 2013) , adipose tissue and skeletal muscle (W. as well as 3T3-L1 adipocytes (Gupte et al., 2008) . Rosiglitazone treatment improved cardiac and renal functions; enhanced atrial natriuretic peptide responses and markedly upregulated renal ACE2 gene transcription in rats with heart failure (Goltsman et al., 2019) . Similarly, rosiglitazone increased vascular ACE2 expression in hypertensive, but not in normotensive rats (Sanchez-Aguilar et al., 2019) . In transgenic diabetic mice, rosiglitazone downregulated renal ADAM17 expression, decreased ACE2 shedding and reduced urinary soluble ACE2, thereby increasing ACE2 protection of the kidneys without altering renal ACE2 expression (Alawi et al., 2020; Chodavarapu et al., 2013) . Notably, although rosiglitazone induced an upregulation of ACE2 mRNA and protein expression in adipocytes of wild type mice, this ACE2 increase was markedly attenuated in adipocytes of fibroblast growth factor 21 (FGF21) knockout mice (Pan et al., 2018) , suggesting that endogenous FGF21 in adipocytes modulates ACE2 expression in an autocrine manner. In a small cohort of patients, pioglitazone treatment improved glucose metabolism, reduced TNF-α expression and enzymatic activity of ADAM17 in skeletal muscle of T2DM patients (Tripathy et al., 2013) .

Glucagon-like peptide 1 (GLP-1), a hormone produced in the distal ileum in response to food intake, activates GLP-1 receptors, increases insulin secretion, reduces glucagon release, and regulates glucose homeostasis. Long-acting GLP-1 receptor agonists, such as liraglutide and exendin-4, are used to treat T2DM. Exendin-4, a clinically used antidiabetic drug and GLP-1 receptor activator, improved pathological changes, decreased renal Ang-II, and completely restored down-regulation of renal ACE2 expression occurring after ureter obstruction (Le et al., 2016) . In diabetic rats with reduced ACE2 levels, liraglutide induced marked upregulation of pulmonary ACE2 gene transcription (Romani-Perez et al., 2015) . In another study, liraglutide increased pulmonary ACE2 expression in rats with in utero growth retardation (Fandino et al., 2018) . Similarly, liraglutide completely reversed reduced hepatic ACE2 mRNA expression in mice with high-fat-induced liver disease through activation of the phosphatidylinositol-3-kinase (PI3K/Akt) signaling pathway in HepG2 cells (M. . Liraglutide and another antidiabetic, linagliptin, a dipeptidyl peptidase-4 (DPP4) inhibitor, improved Ang-II-induced cardiovascular pathology, counteracted Ang-II-induced downregulation of Smad7, reduced collagen synthesis and cardiac fibrosis, and upregulated myocardial expression and activity of ACE2 (L. H. . The DPP4, independently of its enzymatic activity, functions as an entry receptor for the MERS coronavirus, and its co-expression with ACE2 has been shown in bronchial epithelial cells (Radzikowska et al., 2020) . DPP4 inhibitors (gliptins), in addition to their antidiabetic actions, have anti-inflammatory effects, reduce cytokine overproduction, and have been suggested as treatment of COVID-19 (Solerte, Di Sabatino, Galli, & Fiorina, 2020) . However, recent studies reported that gliptins had no significant effect on disease severity, mortality and clinical outcomes in diabetic COVID-19 patients (Y. Chen, D. Yang, et al., 2020; Fadini et al., 2020) . In addition, using Mendelian randomization analysis, a large genome-wide association study has reported that increased ACE2 expression is associated with both type 1 and type 2 diabetes (Rao, Lau, & So, 2020) .

The commonly prescribed oral antidiabetic drug metformin activates the AMP-activated protein kinase (AMPK) in vitro and in vivo (G. Zhou et al., 2001) , resulting in an attenuation of hepatic glucose production and an enhancement of peripheral glucose uptake (G. Zhou et al., 2001) . Metformin also increases AMPK-mediated phosphorylation of ACE2 at Ser680 in human endothelial cell lines, thereby upregulating cell surface ACE2 activity and expression via inhibition of the ubiquitination-related degradation of ACE2 (J. Zhang et al., 2018) . Notably, metformin decreased pulmonary pressure and alleviated pulmonary artery damage in wild type but not in AMPK knock out mice (J. Zhang et al., 2018) . However, in an earlier study in Huh7 cells, metformin had no effect, although activation of AMPK by the AMP mimic AICAR (5-amino-4-imidazolecarboxamide riboside) markedly upregulated ACE2 expression and activity (Clarke, Belyaev, Lambert, & Turner, 2014) . Metformin does not affect renal ACE2 expression or ADAM17 activity, but reduces urinary ACE2 by improving glucose levels in diabetic rats (Somineni, Boivin, & Elased, 2014) . Importantly, metformin activates SIRT1 (Cuyàs et al., 2018) , which is expressed next to the promotor region of the ACE2 gene. Hence increased expression or enhanced functional activation of SIRT1 is associated with an increase in expression of ACE2 . Drugs that increase endosomal pH values (such as chloroquine) are known to reduce viral replication. Metformin has been reported to inhibit the Na + /H + exchanger and the vacuolar ATPase on endosomal membranes and to subsequently increase the endosomal pH (Jeongho Kim & You, 2017) , which potentially interferes with viral replication. In addition, metformin has been shown to reverse established lung fibrosis in mouse models (Rangarajan et al., 2018) , a desirable pharmacological effect in the treatment of lung injury caused by viral pneumonia. Metformin also preserves alveolar capillary permeability and decreases the severity of ventilator-induced lung injury in rabbits (Tsaknis et al., 2012) . It also prolongs survival and attenuates pulmonary injury by reducing pulmonary inflammation, coagulation, and fibrosis in a rat model (X. Chen et al., 2015) . Analysis of one small cohort of COVID-19 patients indicates that the use of metformin is associated with a reduced mortality (Crouse et al., 2020; Hariyanto & Kurniawan, 2020) , whereas another one reports an increased disease progression (Y. Gao et al., 2020) . Of note, it has recently been reported that cyclic sulfonamide derivatives are potent inhibitors (IC 50 = 0.9-3.1 μM) of SARS-CoV-2 in Vero cells (Y. S. Shin et al., 2020) .

Statins, also known as HMG-CoA reductase inhibitors, are a class of lipid-lowering drugs used for decreasing mortality in patients at high risk of cardiovascular disease. Currently, drugs of the statin group are the most common cholesterol-lowering medications. Rosuvastatin was shown to decrease cell proliferation and intimal pathology, and to upregulate aortic ACE2 transcription and protein expression in vascular injury models (Y. H. Li et al., 2013) . On the other hand, pravastatin alone did not exert any protective effect on cardiovascular pathology and did not alter cardiac ACE2 expression, but significantly potentiated cardiovascular protective actions of insulin in diabetic rats (Min et al., 2018) . Similarly, fluvastatin significantly enhanced the cardio-protective effects of insulin, improved cardiac function and restored cardiac ACE2 expression in diabetic rats (Y. H. Shin et al., 2017) . In vascular smooth muscle cell cultures, atorvastatin did not alter ACE2 transcription, but reversed TNF-α induced downregulation of ACE2 expression (Suski et al., 2014) . In another study on statins, atorvastatin improved the lipid disturbance, decreased atherosclerotic pathology and increased cardiac and renal ACE2 protein expression; but ACE2 mRNA expression increased only in cardiac tissue of atherosclerotic rabbits maintained on a high cholesterol diet (Tikoo et al., 2015) . Notably, statins (Carloni & Balduini, 2020; G. Du et al., 2014; Ota et al., 2010) and antidiabetics, such as exenatide, liraglutide (Strycharz et al., 2018) , and sitagliptin (Malvandi, Loretelli, Ben Nasr, Zuccotti, & Fiorina, 2019) , activate SIRT1 and can potentially increase the expression of ACE2 (Clarke Anti RAS effects of heparin also contribute to its antinflammatory and antioxidant actions. Activation of antithrombin III (serine protease inhibitor, serpin) by heparin leads to inactivation of several proteases, such as factor Xa, trypsin, and cathepsin L, which are involved in coagulation and viral replication. (B) Heparan sulfate (HS) (orange inbox; tandem filled orange circles indicate HS or heparin), a structural analog of heparin, binds to (1) S2 protein, (2) the S1/S2 region of S protein (near furin protease cut site) and (3) to the open state of the receptor binding domain (RBD) on the S1 segment of the SARS-CoV-2 spike. On the surface of the host cell, HS polymers are bound extensively to HS proteoglycans (HSPGs) and mediate HSPG-dependent endocytosis of SARS-CoV-2. Heparin competes with HS binding sites and inhibits S protein binding as well as endocytosis of the SARS-CoV-2. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) (Katsiki, Banach, & Mikhailidis, 2020; Katsiki et al., 2018) and to decrease elevated inflammatory markers, e.g., Creactive protein and interleukin-6. They exert anti-inflammatory and immunomodulatory effects (Pirro et al., 2019; Zeiser, 2018 Lu, Liu, & Tam, 2008) and SARS-CoV-2 (H. Wang, Yuan, Pavel, & Hansen, 2020) , have been reported to require lipid rafts for cellular entry. Cholesterol was reported to be involved in binding and altering the oligomeric status of the N-terminal fusion peptide of SARS-CoV, which is essential for virus entry into the host cell (Meher, Bhattacharjya, & Chakraborty, 2019) , and also to interrupt cell-cell fusion induced by the virus (K. S. Choi, Aizaki, & Lai, 2005) . It was shown that cholesterol reduction by methyl-β-cyclodextrin or mevastatin (H. Guo et al., 2017) disrupts lipid rafts that enable the binding of the virus to the host cell, thereby preventing its infection Y. Lu, Liu, & Tam, 2008; Hao Wang et al., 2020) . Conversely, loading of cells with cholesterol (Hao Wang et al., 2020) or increasing the cholesterol concentration in extracellular solutions (C. Wei et al., 2020) increases viral entry. It appears that ACE2 and furin, a protease that cleaves the spike protein of SARS-CoV-2, are preferentially located in cholesterol-rich viral entry points that promote endocytic viral entry mechanisms and facilitate the efficient interaction of the spike protein with ACE2 (Glende et al., 2008; Hao Wang et al., 2020) . Notably, a recent in vitro study investigating the SARS-CoV-2 protein-protein interactome identified the scavenger receptor BI (SR-BI), a cholesterol trafficking receptor, as a potential drug target (Gordon et al., 2020) , and antagonists of SR-BI inhibited SARS-CoV-2 infectivity in Huh7 cell lines (C. Wei et al., 2020) .

25-hydroxycholesterol (25HC) is the product of cholesterol oxidation by the enzyme cholesterol-25-hydroxylase (CH25H). Infection with SARS-CoV-2 has been shown to increase serum 25HC levels in mice and to induce the activity of CH25H in Caco-2 cells (Zu et al., 2020) . Notably, 25HC significantly inhibited SARS-CoV-2 replication with an EC 50 of 3.7 μM and reduced viral protein production in SARS-CoV-2-infected Vero cells. It also decreased the viral RNA load in both lung and trachea of infected mice (Zu et al., 2020) . Another study also reported that the interferon-stimulated gene of CH25H is induced by SARS-CoV-2 infection in vitro and in COVID-19 patients (S. . Furthermore, 25HC inhibited SARS-CoV-2 infection in lung epithelial cells and reduced viral entry in human lung organoids, presumably by preventing viral membrane fusion through activation of the ER-localized acyl-CoA:cholesterol acyltransferase, which leads to the depletion of cholesterol from the plasma membrane (S. . Similar to 25HC, another cholesterol oxidation metabolite, 27-hydroxycholesterol, was shown to inhibit SARS-CoV-2 infection in Vero-E6 cells with an EC 50 of 1.4 μM (Marcello et al., 2020) . Interestingly, serum levels of 27-hydroxycholesterol were significantly decreased (50%) in SARS-CoV-2 infected patients, compared to the control group. In this context, high-density and low-density lipoprotein cholesterol and total cholesterol levels were reported to be significantly decreased in COVID-19 patients (Ressaire, Dudoignon, Moreno, Coutrot, & Dépret, 2020; . Low cholesterol levels were correlated with a higher risk of developing severe events or longer recovery times in some studies (X. Ding et al., 2020; Ressaire, Dudoignon, Moreno, Coutrot, & Dépret, 2020; , but not in another one (Tanaka et al., 2020) .

It is well established that tissue cholesterol increases with age, and this accumulation is directly linked to disease pathologies, including atherosclerosis and inflammation. Remarkably, these diseases are highly comorbid with COVID-19 (Hao Wang et al., 2020) . All these data support the potential use of statins to prevent or reverse host cell lipid raft alterations induced by COVID-19 infection, which could reduce both cell infection and viral replication. Thus, the pharmacological sequestration of cellular or viral cholesterol with statins has potential antiviral effects for preventing both virus attachment and internalization. Furthermore, fluvastatin decreased intracellular reactive oxygen species (ROS) by activating peroxiredoxin 1, a ROS scavenger, reduced proinflammatory responses in cultured cells and inhibited SARS-CoV-2 infection and replication in Vero E6 cells (H. . Pre-infection treatment with pravastatin reduced SARS-CoV-2 infection in Vero E6 cells (Mok et al., 2020) . Finally, pretreatment with atorvastatin, pravastatin or fluvastatin impaired CD147 translocation to the cell surface, altered CD147 expression, structure and function by inhibiting protein isoprenylation and N-glycosylation in cultured monocytes (Sasidhar, Chevooru, Eickelberg, Hartung, & Neuhaus, 2017) and atherosclerotic plaques (X. Liang et al., 2017) . CD147, also known as basigin, EMMPRIN or leukocyte activation antigen M6, is a receptor for the S protein of SARS-CoV and SARS-CoV-2 (K. .

Lipid-lowering effects and some pleiotropic actions of statins, such as the downregulation of CD147 expression and function, disruption of lipid rafts, activation of autophagy, and attenuation of both the inflammatory response and the coagulation activation by these drugs, have been recently reviewed in the context of COVID-19 (Bifulco & Gazzerro, 2020; Katsiki et al., 2020; K. C. H. Lee, Sewa, & Phua, 2020; Radenkovic, Chawla, Pirro, Sahebkar, & Banach, 2020; Rodrigues-Diez et al., 2020) . Noteworthy, the analysis of a randomized control trial in patients with acute respiratory failure suggested that treatment with statins at discharge following an episode of acute respiratory failure was associated with a significant reduction in one-year mortality (Noveanu et al., 2010) . A retrospective cohort study with hospitalized pneumonia patients reported that prior and inpatient use of statins Wang, Zhang, Yuan, Wu, & Li et al. (2015) was associated with decreased mortality rates (Mortensen et al., 2012) . However, in clinical studies with large cohorts of patients, statins were found to be ineffective in patients with ARDS (McAuley et al., 2014) , sepsis-associated ARDS (Truwit et al., 2014) , or ventilator-associated pneumonia (Papazian et al., 2013) . In older adults, a significant association between statin intake and the absence of symptoms during COVID-19 has been reported (De Spiegeleer et al., 2020) . Notably, there are recent reports that the in-hospital use of statins reduced the mortality risk in 1,219 COVID-19 patients (X. J. and in a small cohort of COVID-19 patients admitted to intensive care (Rodriguez-Nava et al., 2020) . Furthermore, in a study with 151 hyperlipidemic COVID-19 patients, treatment with statins was independently associated with lower intensive care admission (Tan, Young, Lye, Chew, & Dalan, 2020) . Similarly, a retrospective cohort study of 249 patients hospitalized with COVID-19 reports a significantly decreased risk of invasive mechanical ventilation in patients treated with statins (S. L. Song et al., 2020) . In addition, in 170 hospitalized COVID-19 patients, the use of statins prior to admission was associated with a lower risk of developing severe COVID-19 and a faster time to recovery among patients without severe disease (Daniels et al., 2020) . Similarly, in 983 diabetic COVID-19 patients, statin use was associated with reduced in-hospital mortality (Saeed et al., 2020) . In addition, a lower SARS-CoV-2 infection-related mortality was observed in 581 patients treated with statins prior to hospitalization (Masana et al., 2020) . However, another recent study with 2449 hospitalized COVID-19 patients with type 2 diabetes concluded that routine statin treatment is significantly associated with increased mortality (Cariou et al., 2020) . The effects of antidiabetic and lipid-lowering drugs on the activity and expression of ACE2 are listed in Table 5 .

Glucocorticoids are mainly produced in the zona fasciculata of the adrenal cortex. When applied therapeutically, they have potent antiinflammatory and immunosuppressive actions with additional metabolic and cardiovascular side effects, such as hypertension, hyperglycemia, and osteoporosis. Animals treated prenatally with glucocorticoids develop hypertension with decreased plasma ACE2 activity and diminished ACE2 expression in renal (P. C. Lu et al., 2016; Shaltout, Figueroa, Rose, Diz, & Chappell, 2009) , cardiac (E. Kim et al., 2015) , and placental (Ghadhanfar et al., 2017) , but not adipose tissue (Massmann, Zhang, Seong, Kim, & Figueroa, 2017; H. R. Yu et al., 2018) . This is associated with reduced Ang-(1-7) in the cerebrospinal fluid (Marshall et al., 2013) . Maternal corticosterone exposure was reported to decrease renal ACE2 expression in females but to increase it in males (Cuffe, Burgess, O'Sullivan, Singh, & Moritz, 2016) . Importantly, glucocorticoids, such as dexamethasone, potentiate Ang-II responses by upregulating the expression of AT1 receptors in cardiac (Xue, Patterson, Xiao, & Zhang, 2014) and vascular structures (Ullian, Walsh, & Morinelli, 1996) . Interestingly, activation of the neutral amino acid transporter SLC6A19 (B 0 AT1), an accessory protein for ACE2 in the intestines, is regulated by the "serum and glucocorticoid inducible kinase" (SGK) isoforms 1-3 (Bohmer et al., 2010) . Of note, budesonide, a glucocorticoid, activates ADAM17 in bronchial epithelial cells (Zijlstra et al., 2014) . However, dexamethasone inhibited ADAM17 activity without affecting its expression level in lipopolysaccharide-activated RAW cells (Chuang et al., 2017) . Corticosteroid medications are commonly used in the treatment of several inflammatory pathologies, including asthma, inflammatory bowel disease (IBD), interstitial lung disease, ARDS, and systemic vasoplegic shock. The results of clinical studies attempting to correlate disease severity with ACE2 expression levels has not been conclusive. In IBD patients not using steroids, no significant change in ACE2 and TMPRSS2 gene expression was found in biopsy samples (Monteleone, Franze, & Laudisi, 2020) . In another study, reduced ACE2 expression in biopsy samples from patients with Crohn's disease was associated with inflammation and worse outcomes (Potdar et al., 2020) . In 138 treatment naïve IBD patients, while ACE2 gene expression was decreased in the ileum, it was increased in colon samples (Krzysztof et al., 2020) . In addition, in control patients, ACE2 expression was 25 times higher in the terminal ilium than in the colon, suggesting anatomical differences in ACE2 expression. In intestinal biopsies of IBD patients, treatment with glucocorticoids was associated with decreased ACE2 expression (Burgueno et al., 2020) . Similarly, the use of corticosteroids, thiopurines and 5-aminosalicylate attenuated ACE2 and TMPRSS2 expression in inflamed colon and rectum (Suárez-Fariñas et al., 2020) .

Clinical studies do not identify asthma as a risk factor of severe COVID-19-related illnesses (Z. Wu & McGoogan, 2020) . Animal models indicate that ACE2 and Ang-(1-7) are protective in asthma (El-Hashim et al., 2012) . In recent studies, ACE2 expression was not altered (Breidenbach et al., 2020; Peters et al., 2020; Radzikowska et al., 2020) or reduced (Jackson et al., 2020; Kimura et al., 2020) in asthmatic patients; but increased expression of TMPRSS2, the enzyme facilitating SARS-CoV-2 entry into host cells, has been reported (Kimura et al., 2020; Radzikowska et al., 2020) . However, in a large cohort study, increased ACE2 gene expression was reported in a sub-group of type 2 asthmatic patients (Camiolo, Gauthier, Kaminski, Ray, & Wenzel, 2020) . Similarly, in bronchial brushings, biopsies and sputum-derived cells of patients with severe asthma, the gene expression of ACE2, TMPRSS2, and furin was positively correlated with asthma severity and glucocorticoid use (Kermani et al., 2020) . However, in a recent study with 268 asthmatic patients, the use of glucocorticoids did not influence the gene expressions of ACE2, TMPRSS2, and furin in bronchial brushes and biopsy samples; and disease severity was not related to changes in these parameters (Bradding et al., 2020) . In another study, the use of inhaled corticosteroids, but not of the synthetic corticosteroid triamcinolone acetonide, was associated with a lower expression of ACE2 and TMPRSS2 in asthmatic patients (Jackson et al., 2020) . In patients with COPD, the administration of inhaled corticosteroids reduced sputum expression of ACE2 compared to controls (Finney et al., 2020) . In this study, it was also shown that inhaled corticosteroids reduced ACE2 expression in airway epithelial cell cultures and mouse models, and the effect was reversed by interferon-β administration. Glucocorticoids, including hydrocortisone, prednisolone, dexamethasone, and methylprednisolone, significantly increased ACE2 protein expression in epithelial cell lines and reduced cytokine interleukin-6 production in human macrophages (Xiang et al., 2020) . In bronchial epithelial cells from specimens of COPD patients, treatment with inhaled corticosteroids significantly decreased the expression of ACE2 and ADAM-17, and it was associated with decreased interferon type-1 gene expression (Stephen Milne et al., 2020) .

In human epithelial cell cultures, the corticosteroid budesonide inhibits the replication of HCoV-229E, which uses aminopeptidase N as entry receptor (Yamaya et al., 2020) . Recently, the glucocorticoid methylprednisolone was reported to increase the survival in a small cohort of COVID-19 positive ARDS patients (C. . In earlier studies, methylprednisolone improved gastrointestinal pathology and accelerated recovery from HCoV infection (Rhoads, Macleod, & Hamilton, 1988) , but it was also reported to promote the replication of HCoV-MHV-3 and to increase the mortality in mice (Fingerote, Leibowitz, Rao, & Levy, 1995) . At clinically relevant concentrations, cortisone increases the replication of infectious bronchitis HCoV in tracheal organ cultures, whereas reproductive hormones, such as progesterone, estrogen, and testosterone, do not have this effect (Ambali & Jones, 1990) . In a recent in vitro study, steroids (glycyrrhetinic, oleanolic acid) and bile acid derivatives inhibited binding of the SARS-CoV-2 spike protein to ACE2 (Carino et al., 2020) . It was also reported that Ciclesonide, an inhaled corticosteroid, suppresses the replication of SARS-CoV-2 with an EC 90 of 0.55 μM in human bronchial epithelial cells (Matsuyama et al., 2020) .

During the previous SARS outbreak, it was reported that high-dose methyl prednisolone had beneficial effects (V. C. Cheng, Tang, Wu, Chu, & Yuen, 2004; Sung et al., 2004; Tsui, Kwok, Yuen, & Lai, 2003; Z. Zhao et al., 2003) . However, a systematic analysis of clinical studies concludes that the results of corticosteroid therapies in SARS-CoV infections are inconclusive and that their application is not recommended (Stockman, Bellamy, & Garner, 2006) . Furthermore, corticosteroid therapies reportedly decrease dendritic and T cells in the circulation (Z. Zhang et al., 2005) , reduce cytokine releasing cells in the spleen (X. Zhang et al., 2008) and suppress cellular immune responses in the lungs (K. Jung et al., 2007) . The use of high steroid doses is also associated with long lasting lipid disturbances (Q. Wu et al., 2017) and an increased risk of avascular necrosis (Sing, Tan, Wong, Cheung, & Cheung, 2020) in recovered SARS-CoV patients. During the recent COVID-19 outbreak, methylprednisolone therapies reportedly improved the clinical prognosis (Y. Wang, W. Jiang et al., 2020; F. Ye et al., 2020) or decreased the mortality rate in COVID-19 patients (Salton et al., 2020) . Additional recent studies report that early, but not late phase (Mongardon et al., 2020) , low-dose corticosteroids decrease mortality and improve COVID-19 clinical outcomes (Ji et al., 2020) . However, another recent study indicates that corticosteroid use is associated with increased mortality and delayed SARS-CoV-2 coronavirus RNA clearance in 409 COVID-19 patients (J. . While some of the metaanalyses conclude that the use of corticosteroids is associated with a higher rate of ARDS in COVID-19 patients (Z. J. J. Y. Zhang, Lee, Ang, Leo, & Young, 2020) , a recent randomized study of several thousands of hospitalized COVID-19 patients reports that dexamethasone reduces the mortality among those receiving invasive mechanical ventilation or oxygen (Horby et al., 2020) . In another study of 396 COVID-19 patients, the use of steroids significantly decreased in-hospital mortality (Fernandez Cruz et al., 2020) , an observation that has been corroborated by several additional recent publications (Bani-Sadr et al., 2020; Chopra et al., 2020; Majmundar et al., 2020) . Corticosteroid activation of glucocorticoid receptors has been suggested to suppress interleukin-6 release and mitigate multiorgan inflammation in some COVID-19 patients (Awasthi et al., 2020) .

Non-steroid anti-inflammatory drugs (NSAIDs) inhibit the cyclooxygenase (COX)-dependent metabolism of arachidonic acid to prostaglandins. Treatments (50 μM, 48 hours) of arachidonic acid, octadecadienoic acid, and docosahexaenoic acid, but not eicosapentaenoic acid and stearic acid, significantly decreased ACE2 mRNA expression in porcine adipocytes (Tseng et al., 2010) . Prostaglandins prevent hypertension and upregulate renal ACE2 protein expression in adult male rats exposed either prenatally to dexamethasone plus postnatally to high fat diet (P. C. Lu et al., 2016) or prenatally to high fructose intake . Lipoxin A4, another product of arachidonic acid metabolism, attenuates lung injury and increases lung ACE2 levels and protein expression in a lipopolysaccharide-induced lung injury model (Q. F. Chen et al., 2018) . Similarly, the lipoxin receptor agonist BML-111 also decreases lung and liver injuries, which are associated with increased ACE2 levels and protein expression in these tissues (Q. F. Chen et al., 2019; Hu et al., 2017) . However, although pharmacological inhibition of soluble epoxide hydrolase, which metabolizes epoxyeicosatrienoic acids, improved disease pathology and increased epoxyeicosatrienoic acid levels, it did not reverse downregulation of cardiac ACE2 expression induced by high-fructose diet intake (Froogh et al., 2020) . 20-Hydroxy-eicosatetraenoic acid (20-HETE), a cytochrome P450-derived arachidonic acid metabolite, increased blood pressure and vascular Ang-II expression. It also upregulated vascular ACE transcription without altering ACE2 expression (K. Sodhi et al., 2010) . In addition, COX-2 and prostaglandin E 2 (PGE2) activate ADAM17 (Al-Salihi et al., 2007) . NSAIDs, through COX-independent mechanisms, promote shedding of L-selectin, a pro-inflammatory cell adhesion molecule, by activating ADAM17 and generating superoxide anions at the plasma membrane through NADPH-oxidase activation. They thereby interfere with neutrophil-endothelial cell adhesion (Dominguez-Luis et al., 2013; Gomez-Gaviro et al., 2002) and potentially decrease cell surface activity of ACE2.

Activation of both COX-1 and COX-2 mediates some of the Ang-II responses, such as hypertension, oxidative stress, and inflammation (Sriramula, Xia, Xu, & Lazartigues, 2015; R. Wu, Laplante, & de Champlain, 2005) . Pharmacological inhibition or genetic deletion of COX-1 reduces the acute pressor effects of Ang-II in murine disease models (X. Cao et al., 2012; Z. Qi et al., 2002; Sriramula, Xia, Xu, & Lazartigues, 2015) . COX-2 inhibition by rofecoxib and nimesulide attenuates Ang-II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats (R. Wu, Laplante, & de Champlain, 2005) . Thus, over-expression of ACE2 in the brain decreases blood pressure, oxidative stress and inflammation; it also down regulates COX expression in murine hypertension models (Sriramula et al., 2015) . However, vasodilatatory and cardioprotective effects of Ang-(1-7) are also mediated by activation of COX, and these effects are inhibited by indomethacin, a non-selective COX inhibitor (X. Liao et al., 2011) . Therefore, while some of the effects of NSAIDs potentiate Ang-II actions, others counteract Ang-II. Furthermore, all NSAIDs except ketoprofen, through COX-independent mechanisms, inhibit SIRT1 deacetylase (Dell'Omo et al., 2019) , which counteracts upregulation of ACE2 by SIRT1 . Importantly, SIRT1 expression was reported to be upregulated in the lungs of COVID-19 patients with comorbidities (Pinto et al., 2020) .

Ibuprofen, a commonly used NSAID and non-selective COX inhibitor, attenuates cardiac fibrosis and upregulates cardiac ACE2 expression in streptozotocin-induced diabetic rats (Qiao et al., 2015) . Other NSAIDs, including rofecoxib, meloxicam, celecoxib and flurbiprofen, at clinically relevant doses, were shown to induce modest increases in renal and cardiac ACE2 protein expression in adjuvant-induced arthritic rats (Asghar, Aghazadeh-Habashi, & Jamali, 2017) .

The SARS-CoV has been shown to directly bind to the COX-2 promotor and to increase its expression (Yan et al., 2006) . COX-2-dependent PGE2 was reported to attenuate the chronic antiviral lymphocyte response of unresolved viral infections (Schaeuble et al., 2019) , suggesting that NSAIDs may have beneficial effects in the treatment of SARS-CoV-2 infection. However, two previous meta-analyses have shown that the use of NSAIDs, including ibuprofen, is associated with increased venous thromboembolism and increased risk of vascular events (T. Lee et al., 2016; Ungprasert, Srivali, Wijarnpreecha, Charoenpong, & Knight, 2015) . NSAIDs increase the risk of thromboembolism (Schmidt et al., 2011) , stimulate salt intake and enhance renal and pulmonary vasoconstriction (Cumhur Cure, Kucuk, & Cure, 2020; Harrington et al., 2008; Varga, Sabzwari, & Vargova, 2017) , which are undesirable pharmacological actions in the treatment of COVID-19. In addition, observational studies suggest an association between pre-hospital NSAID exposure and a protracted and complicated course of pneumonia (Voiriot et al., 2019) . Therefore, it has been recommended to use NSAIDs at the lowest effective dose for the shortest possible period, and, instead, in most cases, to use paracetamol (acetaminophen) as the first treatment option for fever or pain associated with infections (Zolk et al., 2020) . Interestingly, indomethacin, a non-selective COX inhibitor, has antiviral effects with an EC 50 of 5 μM for SARS-CoV, as demonstrated in human cell lines and by in vivo experiments (Amici et al., 2006) . However, the effect of indomethacin is independent of COX inhibition, since high concentrations of aspirin do not have an antiviral activity. In clinical studies of small cohorts of COVID-19 patients, treatment with NSAIDs was associated with either adverse clinical outcomes (Jeong et al., 2020) or no effect on mortality rate (Abu Esba et al., 2020; Chandan et al., 2020; Lund et al., 2020) or a modest beneficial effect on survival rates (Bruce et al., 2020) . The mechanisms of NSAID actions and their potential use in COVID-19 patients have recently been discussed (Cabbab & Manalo, 2020; Micallef, Soeiro, & Jonville-Béra, 2020) . The effects of steroids, NSAIDs, and pharmacologically related compounds on ACE2 activity and expression are summarized in Table 6 .

Activation of vitamin D receptors (VDR) by 1,25-dihydroxyvitamin D (calcitriol) or pharmacologic VDR agonists is important for the control of phosphate and calcium homeostasis and bone remodeling but could also have beneficial effects by reducing the risk of cardiovascular morbidity and mortality, diabetes, autoimmune diseases, and cancer. Vitamin D3 supplementation was shown to upregulate cardiac ACE2 gene expression in normotensive rats; whereas vitamin D3 deficiency had no effect on ACE2 expression (Machado, Ferro Aissa, Ribeiro, & Antunes, 2019) . Similarly, vitamin D deficiency did not affect serum ACE2 levels in a transgenic hypertension model (Andersen et al., 2015) . In spontaneously hypertensive rats with an overactive RAS, calcitriol decreased oxidative stress, markedly reduced Ang-II formation, and upregulated brain ACE2 expression (C. Cui et al., 2019) . Interestingly, in these experiments, calcitriol also upregulated ACE2 expression in the brains of normotensive rats, as well as in cultured BV2 retroviral immortalized microglial cells. Calcitriol, an active metabolite of vitamin D3, inhibited Ang-II and renin expression, decreased vascular permeability and cell death, and reversed lipopolysaccharideinduced downregulation of ACE2 in pulmonary tissue and vascular endothelial cells (J. Xu et al., 2017) . Similarly, calcitriol increased renal ACE2 expression in diabetic rats with compromised ACE2 activity and counteracted glucose-induced downregulation of ACE2 by inhibiting p38 MAPK and ERK phosphorylation in NRK-52E cells (M. Lin et al., 2016) . In type I non-obese diabetic rats, paricalcitol, a synthetic vitamin D analog, decreased serum ACE2 activity, renal oxidative stress, and circulating H 2 O 2 levels. Although renal ACE2 activity was not altered, renal ADAM17 was reduced by paricalcitol (Riera et al., 2016) . Importantly, in this study, paricalcitol upregulated ACE2 mRNA expression in epithelial cell lines in a dose-dependent manner. In line with these findings, paricalcitol inhibits aldosterone-induced upregulation of the ADAM17/ TGF-α/EGF receptor pathway in cultured tubular epithelial cells (Morgado-Pascual et al., 2015) . Vitamin D has been shown to suppress ADAM17 expression in A431 cell lines (Arcidiacono, Yang, Fernandez, & Dusso, 2015) and in parathyroid cells (Dusso, Arcidiacono, Yang, & Tokumoto, 2010) .

A recent study reports that vitamin D attenuates lung injury by stimulating epithelial repair, reducing epithelial cell apoptosis, and decreasing TGF-β levels . In animal experiments, it has been demonstrated that vitamin D reduces disease severity of coronaviruses (J. Yang et al., 2019) by regulating autophagy, enhancing cathelicidin production and inhibiting intestinal mucosa interleukin (IL)-6 and IL-8 mRNA expression, thereby lessening the severity of damage (Yuk et al., 2009) . Vitamin D reduces the susceptibility to acute lung injury by inhibiting renin and consequently Ang-II biosynthesis (Zittermann et al., 2018) . In addition, vitamin D reportedly reduces disease severity and decreases the risk of respiratory tract infections in a large cohort of adults (Zittermann, Pilz, Hoffmann, & Marz, 2016) . In line with these findings, a recent meta-analysis study indicates that the use of vitamin D is associated with a reduced risk of acute respiratory infections, and administration of daily doses of 400-1000 IU vitamin D for up to 12 months was found to have a protective effect (Jolliffe et al., 2020) . In a randomized controlled trial of school children, daily vitamin D intake resulted in a 58% reduction of the relative risk of influenza A, compared to the placebo group (Urashima et al., 2010) . Importantly, post-infection treatment with 10 μM calcitriol significantly reduced SARS-CoV-2 infection in Vero E6 and human epithelial cells (Mok et al., 2020) . In several recent studies on small cohorts of COVID-19 patients, vitamin D deficiency has been identified as an independent risk factor for increased mortality or a higher rate of intensive care admission and disease severity (Abrishami et al., 2020; Arvinte, Singh, & Marik, 2020; Baktash et al., 2020; Brenner, Holleczek, & Schöttker, 2020; Carpagnano et al., 2020; Hernández et al., 2020; Macaya et al., 2020; Munshi et al., 2020; Panagiotou et al., 2020; K. Ye et al., 2020) . Vitamin D deficiency was also associated with increased SARS-CoV-2 positivity rates and infection (Kaufman, Niles, Kroll, Bi, & Holick, 2020; Merzon et al., 2020) . Conversely, vitamin D supplements were reportedly associated with a less severe disease progress and faster recovery rates in COVID-19 patients (C. G. Annweiler et al., 2020; Rastogi et al., 2020; . Vitamin D supplementation has recently been reviewed (Grant et al., 2020; Malek Mahdavi, 2020; Tay, Mahajan, & Thornton, 2020) with the conclusion that it is effective in boosting the immune system, strengthening the lung epithelial barrier, and preventing an excessive inflammatory response and viral infections.

All-trans retinoic acid (atRA), a biologically active metabolite of vitamin A, modulates gene transcription and exerts its other effects by binding to the retinoic acid receptor, and interfering with transcription factors. atRA reduced the blood pressure, attenuated myocardial damage, and significantly upregulated cardiac and renal ACE2 expression in spontaneously hypertensive rats (Zhong et al., 2004) . However, chronic atRA treatment did not have an effect on the expression of ACE2 in non-hypertensive rats (Zhong et al., 2004) , suggesting that atRA can potentially be used in the treatment of hypertension. atRA decreased oxidative stress and Ang-II production; it also upregulated mitogen-activated protein kinase phosphatase (MKP)-1, MKP-2 and cardiac ACE2 expression in rats with pressure overload-induced cardiac remodeling (Choudhary et al., 2008) . In rats with glomerulosclerotic lesions, atRA reduced glomerular lesions and Ang-II expression; it also markedly upregulated renal ACE2 mRNA and protein expression (T. B. Zhou, Drummen, Jiang, Long, & Qin, 2013) . Treatment with atRA decreased the formation of reactive oxygen species, Ang-II expression and reversed the downregulation of ACE2 expression due to hypoxiainduced injury in renal tubular epithelial cells (T. B. Zhou, Ou, Rong, & Drummen, 2014) . Importantly, vitamins D (Strycharz et al., 2018) , C (Aşcı et al., 2016; M.-Z. Qi et al., 2018) , A (A. N. Shin et al., 2018) , and B3 (Hong et al., 2018) have been shown to activate SIRT1, suggesting that they can upregulate ACE2 expression . In addition, atRA upregulates mRNA expression (Flannery, Little, Caterson, & Hughes, 1999) and promotes activation as well as translocation of ADAM17 to the cytoplasm (Koryakina, Aeberhard, Kiefer, Hamburger, & Kuenzi, 2009) , suggesting that atRA can potentially modulate ACE2 shedding through ADAM17 as well. Effects of vitamins on the activity and expression of ACE2 are presented in Table 7 .

Due to the pivotal role of ACE2 as entry receptor of SARS-CoV2, the prevention of SARS-CoV-2 spike protein-ACE2 interaction and subsequent viral infectivity is an important antiviral treatment strategy. In earlier studies, soluble ACE2 was able to block the replication of SARS-CoV in HEK-293T cells (Wenhui Li et al., 2003) . Recombinant soluble human ACE2 fused to the Fc region of the human immunoglobulin IgG1 to increase short half-life of soluble ACE2 (Iwanaga et al., 2020; Lei et al., 2020) and human recombinant soluble ACE2 (Monteil et al., 2020) have been shown to inhibit SARS-CoV-2 infection in cell lines, engineered human blood vessels and kidney organoids. Recently, peptides mimicking the N-terminal helix of the human ACE2 protein, which contains most of the contacting residues for the S proteinbinding site, were shown to block infection of human pulmonary cells with SARS-CoV-2, with IC 50 values in the range of 60-800 nM (Karoyan et al., 2020) . Similarly, ACE2 peptides optimized to SARS-CoV-2 spike protein binding regions using protein-engineering methods potently bound to the spike protein with a 170-fold higher Asghar, Aghazadeh-Habashi, and Jamali (2017) affinity than wild-type ACE2 and inhibited SARS-CoV-2 infection (IC 50 of 28 ng/ml) in cell lines (Glasgow et al., 2020) . In another set of experiments, a fusion protein consisting of ACE2 and an immunoglobulin Fc protein effectively blocked SARS-CoV-2 infection in HEK-293T cells with an IC 50 of 4 μg/mL (Y. .

In an earlier study, a compound coined SSAA09E2 has been shown to block the binding of the SARS-CoV spike protein to ACE2 and to inhibit SARS-CoV infection in ACE2 expressing HEK-293T cells with an EC 50 of 3.1 μM (Adedeji et al., 2013) . Chloroquine and hydroxychloroquine, in addition to their pH elevating effects in endosomes, bind to ACE2 (N. , impair the terminal glycosylation of ACE2 (Vincent et al., 2005) and inhibit SARS-CoV replication (Al-Bari, 2017; Keyaerts, Vijgen, Maes, Neyts, & Van Ranst, 2004) . They also prevent the entrance of SARS CoV-2 spike protein into ACE2 expressing cell lines (N. . Results from recent studies reveal that chloroquine and, more effectively, hydroxychloroquine also inhibit the replication of SARS-CoV-2 in simian Vero cells (X. Yao et al., 2020) . TAPI-2, an inhibitor of TNF-α converting enzyme (ADAM17), blocks SARS-CoV S protein-induced shedding of ACE2 and inhibits SARS-CoV cell entry (Haga et al., 2010) . Recently, ceftazidime, an antibiotic, was shown to inhibit SARS-CoV spike protein-ACE2 interaction and to prevent SARS-CoV-2 pseudovirus infection of ACE2-expressing HEK-293T cells (C. . Finally, various antiviral compounds, such as emodin, baicalin and green tea extracts found in Chinese herbs, are reviewed in other chapters of this review.

Drugs used for cardiovascular diseases and diabetes, as described in earlier sections, significantly interact with ACE2, due to important roles of the ACE2/Ang-(1-7)/Mas receptor axis in the pathogenesis of these diseases. However, some anticancer agents, antibiotics, and other drugs also modulate the activity and expression of ACE2. For example, propofol, an intravenous anesthetic, activates the phosphatidyl-inositol 3-kinase (PI3K)/Akt signaling pathway and upregulates ACE2 expression in human pulmonary endothelial cells (L. Cao, Xu, Huang, & Wu, 2012) . Similarly, propofol prevents Ang-II-induced apoptosis and oxidative stress, increases NOS phosphorylation, and upregulates ACE2 protein expression in human umbilical vein endothelial cells (L. Zhang et al., 2018) . Some other drugs, such as certain anticancer agents and antibiotics, also reportedly affect ACE2 activity, and a list of these drugs and pharmacological agents is provided in Table 8 .

In recent years, potential health and therapeutic benefits, nutritional values, and biological activities of phytochemicals, natural products and their bioactive compounds have been intensively studied. Among the vast number of these compounds, some phytochemicals can affect the activity and expression of ACE2.

Curcumin, a pigment extracted from the rhizomes of the turmeric plant Curcuma longa, exhibits diverse pharmacologic characteristics, such as anti-oxidant, anti-inflammatory, and anti-fibrotic properties. In rats subjected to Ang-II infusion, curcumin significantly decreased the arterial blood pressure, reduced AT1 receptor expression and upregulated the AT2 receptor. Along with these modulations, curcumin decreased the number of macrophages and myofibroblasts; it also inhibited collagen synthesis and tissue fibrosis, which were accompanied by reduced expression of TGF-β1 and phosphorylated-Smad2/3 . Importantly, curcumin upregulated ACE2 protein expression in cardiac tissue, suggesting beneficial effects of curcumin in cardiac fibrosis. In another study, treatment with a curcumin analog reduced serum creatinine, urea nitrogen and urine albumin; it decreased Ang-II, improved renal pathology and upregulated renal ACE2 protein and mRNA expression in diabetic rats (X. Xu, Cai, & Yu, 2018) . In addition, curcumin and its amino acid conjugates upregulate ADAM17 expression in HEK-293 cells (Narasingappa et al., 2012) , suggesting that curcumin can modulate ACE2 shedding. Curcumin, at a concentration of 20 μM, was found to inhibit SARS-CoV-induced cytopathogenic effects in Vero-E6 cells (Wen et al., 2007) . Beneficial effects of curcumin in the context of COVID-19 have been reviewed recently (Zahedipour et al., 2020) .

Embelin, a naturally occurring para-benzoquinone isolated from dried berries of false black pepper (Embelia ribes) plants with antioxidant, anti-inflammatory, antidiabetic, and analgesic effects, has been shown to inhibit ADAM17 expression and activity in cancer cell lines (Dhanjal et al., 2014) , suggesting that embelin potentially upregulates ACE2 activity by inhibiting ADAM17 mediated shedding. Similarly, 4-Hydroxyisoleucine, a plant-derived antidiabetic compound extracted from the seeds of fenugreek (Trigonella foenum-graecum), has been shown to downregulate ADAM17 expression in 3T3-L1 adipocytes (F. and HepG2 cells (F. .

Resveratrol, a stilbenoid and natural polyphenol that is found in high concentrations in the skins of red wine grapes (Vitis vinifera), in red Choudhary et al. (2008) wine and in sprouted peanuts (Arachis hypogaea), reportedly has beneficial cardiovascular and metabolic actions. Resveratrol decreased adipose tissue mass, improved insulin-sensitivity and glucose tolerance, lowered plasma levels of glucose and lipids and upregulated ACE2 mRNA expression through activation of SIRT1 in adipocyte cell cultures and adipose tissue from FVB/N mice fed on a high fat diet (Oliveira Andrade et al., 2014) . The improved metabolic profile induced by resveratrol was associated with marked up-regulation of glucose transporter type 4 (GLUT4) in adipose tissue. GLUT4, a key protein in glucose metabolism, exerts its influence by stimulating protein AMPactivated protein kinase (AMPK) and phosphorylating forkhead/ wingedhelix O (FoxO)1. Administration of resveratrol prevented the development of liver pathology in rats fed maternally and postnatally on a high fat diet. Antioxidant, anti-apoptotic, and lipid metabolism regulating actions of resveratrol are associated with upregulation of SIRT1, leptin and ACE2 mRNA and protein expression in the liver (Tiao et al., 2018) . In thoracic aortas of aging rats, resveratrol reduced serum Ang-II, increased Ang-(1-7) levels, and upregulated protein expression of ACE2, along with expression of AT2 and Mas receptors (E. N. Kim et al., 2018) . In apolipoprotein E-deficient mice fed on a high fat diet, resveratrol reduced the development of aortic aneurysms, elevated serum ACE2 levels and upregulated aortic tissue levels of ACE2 and SIRT1 activity, but decreased the phosphorylation of Akt and ERK1/2 (Moran et al., 2017) . Since activation or increased expression of SIRT1 is associated with the induction of ACE2 expression , activation of SIRT1 by phytochemicals, such as resveratrol (Borra, Smith, & Denu, 2005; E. N. Kim et al., 2018; Moran et al., 2017) and curcumin (Zendedel, Butler, Atkin,& Sahebkar, 2018) , can potentially mediate ACE2 upregulation by these compounds. In addition, resveratrol has been shown to decrease inflammation and increase ADAM17 expression through SIRT1 activation in a colonic inflammation model (Sharma et al., 2014) . It has also been demonstrated that resveratrol inhibits MERS-CoV infections (S. C. Lin et al., 2017) , and some of its substituted derivatives possess antiviral activity against SARS-CoV (Y. Q. Li et al., 2006) . Thus, resveratrol and its analogs may be effective against SARS-CoV-2 infection, too, as it was found to form highly stable bounds with the viral protein-ACE2 receptor complex in silico (Wahedi, Ahmad, & Abbasi, 2020) . In a recent study, resveratrol showed an antiviral effect (IC 50 = 66 μM), inhibiting SARS-CoV-2 replication and infection in Vero-E6 and human bronchial epithelial cells (Ellen ter et al., 2020) . Another polyphenol. quercetin (IC 50 = 4.5 μM) and its metabolites have been shown to inhibit the enzymatic activity of human ACE2 in a concentration-, time-and temperature-dependent manner (X. Liu, Raghuvanshi, Ceylan, & Bolling, 2020) . Among other plant-based compounds, nicotianamine, isolated from soybean, was reported to be a potent inhibitor of human ACE2 activity with an IC 50 of 84 nM (Takahashi, Yoshiya, Yoshizawa-Kumagaye, & Sugiyama, 2015) . Recently, it was reported that organosulfur compounds, such as allyl disulfide and allyl trisulfide found in garlic, interact strongly with human ACE2 and the main protease PDB6LU7 of SARS-CoV (Thuy et al., 2020) . GB-2, the formula from the Holy Heavenly Mother Peitian Temple in Puzi, Chiayi County, was widely used for the prophylaxis of SARS-CoV-2 infection in Taiwan. It was shown that GB-2 significantly decreased ACE2 protein and mRNA expression in HepG2 and HEK-293T cells in a concentration-dependent (10-250 μg/ml) manner (C. Y. . Biological activities of organic compounds used in Traditional Chinese medicine (TCM) have been the subject of considerable investigations, especially in the fields of cardiovascular and cancer research. Several commonly used TCM compounds have been reported to influence the activity and expression of ACE2. A detailed list of phytochemicals and naturally occurring substances is provided in Table 9 . The antiviral actions of these compounds on coronaviruses in general have been reviewed in detail recently (Islam et al., 2020; Mani et al., 2020) . Astragaloside III, a triterpenoid saponin isolated from Astragali Radix, a widely used herb in TCM, has potent anti-inflammatory and antiatherosclerotic effects. In endothelial cells, astragaloside III activates growth factor signaling through the p38 signaling pathway and upregulates ADAM17 (H. , suggesting that cell surface ACE2 shedding can be modulated by astragaloside III. Similarly, paeoniflorin, another traditional Chinese medicine compound extracted from Paeoniae Radix, induces Src kinase dependent activation of ADAM17 in vascular endothelial cells (H. . Tanshinones, a class of abietane diterpene phytochemicals isolated from Salvia miltiorrhiza, a well-known herb used in TCM, are known to have anti-inflammatory and anti-oxidant effects; they are used for the treatment of cardio-and cerebrovascular diseases (Z. Jiang, Gao, & Huang, 2019) . Tanshinone IIA attenuates pulmonary fibrosis and lung injury; it also upregulates pulmonary ACE2 mRNA and protein expression (Y. H. Wu et al., 2014) . Moreover, tanshinones inhibit SARS-CoV cysteine proteases, suggesting antiviral effects (J. Y. Park et al., 2012) . In addition, abietane diterpenoids with a chemical structures similar to tanshinones, and labdane type diterpenoids potently inhibit SARS-CoV replication and virus-induced cytopathogenic effects in Vero-E6 cells with IC 50 values ranging from 1.4 μM to 7.5 μM (Wen et al., 2007) . Chemical components of the Lianhuaqingwen capsule, a commonly used antiviral TCM containing neochlorogenic acid, amygdalin, prunasin, forsythoside I, rutin, forsythoside A, and rhein, exhibited binding affinities to ACE2 with K D values ranging from 0.2 to 82.4 μmol/L, interrupted SARS-CoV-2 spike protein binding to ACE2 with different efficacies (X. , inhibited SARS-CoV-2 replication in Vero-E6 cells and reduced pro-inflammatory cytokine expression in Huh-7 cells (Runfeng et al., 2020) . Glycyrrhizin and its derivatives, active components of liquorice roots used in TCM, bind to ACE2 (K D of 4.4.μmol/L) and inhibit the interaction of SARS-CoV-2 spike protein with ACE2 (S. Yu et al., 2020) . They also decrease the replication of SARS-CoV (Hoever et al., 2005) and SARS-CoV-2 in cell lines (X. S. Yu et al., 2020) . Baicalin, a flavonoid isolated from the roots of Scutellaria baicalensis Georgi (Huang Qin) used in TCM, has anti-oxidative, anti-viral, anti-inflammatory, anti-HIV and antiproliferative activities. Baicalin increased ACE2 mRNA and protein expression in human umbilical vein endothelial cells treated with Ang-II (X. Wei et al., 2015) . Baicalin also showed an antiviral activity against SARS-CoV in fRhK4 and Vero-E6 cells (F. Chen et al., 2004) . In addition, baicalin inhibited the replication of the porcine reproductive and respiratory syndrome virus, remotely related to SARS-CoV (Karuppannan, Wu, Qiang, Chu, & Kwang, 2012) . It has been reported that green tea extracts, in a concentration range of 0.1to 0/8 mg/ml, are potent inhibitors of pseudotyped SARS-CoV and SARS CoV-2 infection by disrupting the binding of the spike protein to ACE2 (Joseph, T, Ajay, Das, & Raj, 2020) . Emodin, another compound used in TCM, which can be isolated from rhubarb and buckthorn, reportedly inhibits the binding of SARS-CoV spike protein to ACE2 (Ho, Wu, Chen, Li, & Hsiang, 2007) . Naringenin, a citrus fruit flavonoid, has been shown to inhibit SARS-CoV-2 infection in Vero-6 cells (Clementi et al., 2020) , decrease the expression of the proinflammatory cytokines in Raw macrophage cells, and potentially bind to ACE2 (L. Cheng et al., 2020) . In summary, several compounds used in TCM not only affect ACE2 expression, but also possess antiviral activities, which have been reviewed recently (F. Huang Table 9 Effects of phytochemicals and naturally occurring compounds on the activity and expression of ACE2. Y. F. Huang, Bai, He, Xie, & Zhou, 2020; C.Li, Wang, & Ren, 2020) . Elucidation of the full range of their pharmacological activities will not only benefit cardiovascular, diabetic, and cancer research, but may also aid in the development of new antiviral drugs. Finally, the relationship between oxidative stress and ACE2 activity needs to be adressed briefly, since several naturally occurring compounds are known to have antioxidant properties, and ACE2 activity alleviates oxidative stress. Ang-II, as a known promoter of oxidative stress, increases the production of reactive oxygen species and superoxide levels; it also upregulates the expression and activity of enzymes involved in oxidative stress. ACE2, on the other hand, decreases oxidative stress by degrading Ang-II, and producing Ang-(1-7), which promotes antioxidant effects. Overexpression of catalase, a key antioxidant enzyme, decreases oxidative stress, hypertension, and renal fibrosis, normalizes renal functions, and upregulates renal ACE2 protein expression in diabetic Akita mice (Shi et al., 2013) . Overexpression or pharmacological activation of ACE2 reduces oxidative stress, improves endothelial and vascular functions, increases Ang-(1-7) production, and promotes NOS phosphorylation (Y. . In another study, Ang II-induced hypertension, renal oxidative stress, and tubuleinterstitial fibrosis were significantly reduced by treatment with recombinant human ACE2 (rhACE2) and, conversely, exacerbated in ACE2 knock out mice (J. . Similarly, in human smooth muscle cells, Ang-II induced superoxide generation and pro-inflammatory cytokine production. Activation of the JAK2-STAT3 and ERK1/2 signaling pathway was markedly reduced by rhACE2; conversely, they were aggravated by the ACE2 inhibitor DX600 (B. Song et al., 2013) . Tempol, a superoxide dismutase mimetic, antioxidant and nutritional supplement, decreases high blood pressure in obese Zucker rats. In this animal model, it also reduces renal oxidative stress, improves renal functions and markedly upregulates renal ACE2 mRNA and protein expression . Tempol and another antioxidant, α-lipoic acid, reverse Ang-II-or deoxycorticosterone-induced down-regulation of ACE2 expression and upregulation of ADAM17 (de Queiroz, Xia, Filipeanu, Braga, & Lazartigues, 2015) . Interestingly, α-lipoic acid treatment markedly downregulated the overexpression and the activity of ADAM17 in Neuro2A cells (de Queiroz, Xia, Filipeanu, Braga, & Lazartigues, 2015) . Tempol upregulates renal ACE2 protein expression in both high salt intake and control rats (G. Cao et al., 2017) . In cerebral arteries, tempol reduces vascular dysfunctions linked to increased oxidative stress promoted by genetic deficiency of ACE2 and aging (Peña . Of note, tempol also decreases viral load, ameliorates encephalomyelitis and lessens the inflammation induced by CoV-MHV-59A (Tsuhako et al., 2010) . Potential action mechanisms and the role of antioxidants in SARS-CoV-2 infection have been reviewed recently (Suhail et al., 2020) .

In summary, ACE2 plays an important regulatory role in counteracting the deleterious effects of the Ang-II/ACE/AT1 receptor axis on cardiovascular and metabolic events. Thus, not surprisingly, a vast number of drugs, including some vasodilators, diuretics, steroids, NSAIDs, and some of the antidiabetic and cholesterol-lowering drugs, significantly affect the activity and expression of ACE2. In addition, some vitamins, phytochemicals, and various naturally occurring organic compounds employ the ACE2/Ang-(1-7)/Mas receptor axis to exert their beneficial effects. Considering the crucial role of ACE2 in coronavirus infections, potentially deleterious consequences of ACE2 upregulation by RAS inhibitors have been the subject of much recent debate, and, so far, evidence from clinical and epidemiological studies indicates that these drugs do not negatively affect the susceptibility and prognosis of COVID-19. It remains to be seen whether other drugs and pharmacologically active substances affect coronavirus susceptibility or disease prognosis.

Apparently, while some of the in vitro and in vivo experiments indicate no alterations, the majority of preclinical studies report a significant upregulation of ACE2 by RAS inhibitors in various tissues and organ preparations. Thus, there seem to be significant discrepancies between the results of these preclinical experiments and clinical studies. The following points can be considered to clarify some of these discrepancies. Peak plasma concentrations of ARBs at the daily adult therapeutic dose range are approximately 0.6 μM for losartan and 4.6 μM for valsartan. These values for ACE-Inhs., such as captopril, ramipiril, and lisinopril, are 3.4 μM, 0.1 μM, and 0.1 μM, respectively (Sriram & Insel, 2020) , with considerably lower plasma concentrations attained during steady-state levels of maintenance therapies. In addition, typical treatment times for ACE-Inhs. and ARBs in animal studies are considerably shorter than clinical treatment durations for these drugs. Moreover, in the majority of these preclinical studies, concentrations were significantly higher than clinically advised. Thus, the data obtained from high-dose acute phase experiments may not be applicable to lower dose chronic phase experiments where receptor-dependent cellular adaptations can take place. Thus, experimental conditions in which mostly high drug concentrations are used for relatively short durations may not be comparable to the clinical use of these drugs, where lower maintenance concentrations are administered over several months or years. Numerous adaptation mechanisms, at the cellular, organ and organsystem levels, can develop, especially during long administration periods.

Importantly, in the majority of preclinical experiments, the regulatory actions of these drugs are described under disease situations. Thus, the reported effects on the expression or activity of ACE2 in animal studies could merely represent a normalization of ACE2 levels, rather than de novo expression of ACE2 in response to RAS inhibitors. Finally, often tissue-, species-, and gender-dependent effects of drugs can contribute to the observed pharmacological response. Therefore, vis-à-vis direct interpolation of preclinical data to clinical conditions may not be applicable for a given situation. For example, while rodents and humans share more than 80% sequence identity in their ACE2 protein, SARS-CoV cannot replicate through ACE2 in rodents (Gembardt et al., 2005; W. Li et al., 2004; McCray et al., 2007) . Similarly, compounds efficiently activating ACE2 in humans can be ineffective in rodents or vice versa (Joshi, Balasubramanian, Vasam, & Jarajapu, 2016; Pedersen, Sriramula, Chhabra, Xia, & Lazartigues, 2011; Ye et al., 2012) . Expression and activity of ACE2 shows significant variations among different cell types and organs. Expression of ACE2 in intestines and kidneys is more than two orders of magnitude higher than in lungs (Y. Chen, Guo, Pan, & Zhao, 2020; Hamming et al., 2004; Yiliang Wang et al., 2020) . In fact, the activity of ACE2 in lungs is considerably low, and most of Ang-II conversion to Ang-(1-7) in pulmonary tissue is carried out through peptidases other than ACE2, whereas Ang-(1-7) formation in the kidney is mainly ACE2-dependent (Serfozo et al., 2020) . It is unclear whether modest changes in ACE2 expression in lungs (< 2-fold, from most preclinical data) can impact the high infectivity of SARS-CoV-2 in host tissues (Sriram & Insel, 2020) .

In addition, gender-dependent expression of the ACE2 gene, which is located on the X-chromosome, is suggested to impact the pathogenesis of diseases, such as hypertension (Ji et al., 2020) and COVID-19 (Klein et al., 2020) . Moreover, the shedding process of ACE2 adds a further layer of complexity to the interpretation of ACE2 levels in biological fluids. Increased ACE2 levels in urine, cerebrospinal fluid, and plasma may in fact correspond to a decreased ACE2 activity at the tissue level (Anguiano, Riera, Pascual, & Soler, 2017; A. Gilbert et al., 2019; Palau, Pascual, Soler, & Riera, 2019; Úri et al., 2014) . Nevertheless, both in vitro and in vivo experiments provide crucial information on the action mechanisms of drugs and guidance for further clinical studies. The knowledge of the pharmacological regulation of ACE2 by various drugs and compounds greatly helps to better understand how these molecules work at cellular and organ system levels.

As mentioned earlier, interruption of SARS-CoV-2 spike protein binding to ACE2 is a feasible treatment strategy against COVID-19. For this purpose, the application of soluble ACE2 fragments, ACE2 antibodies, recombinant ACE2, and Ang-(1-7) peptides have been proposed as alternative therapeutic approaches. Of note, pharmacological inhibition of ACE2 by MLN-4760 does not affect the interaction of SARS-CoV spike protein with ACE2 nor does it affect the SARS-CoV infection of HEK-293T cells expressing human ACE2 (W. Li et al., 2005) . Furthermore, the SARS-CoV spike protein does not alter ACE2 activity (W. Li et al., 2005) . Thus, not surprisingly, while some compounds that block spike protein binding to ACE2 do not inhibit the catalytic activity of ACE2 peptidase, some other compounds with strong inhibitory effects on the enzymatic activity of ACE2 have no antiviral actions (X. . However, another ACE2 inhibitor, N-(2-aminoethyl)-1 aziridine-ethanamine, was found to be effective in blocking the SARS-CoV spike protein-mediated cell fusion (Huentelman et al., 2004) , indicating an allosteric communication between the active site of ACE2 and its site of interaction with SARS-CoV spike protein. Furthermore, recently, binding of SARS-CoV-2 trimeric spike protein was shown to increase the proteolytic activity of ACE2 (J. Lu & Sun, 2020) . Thus, it is conceivable that new drugs may be developed that bind to the active site of ACE2 and disrupt the interaction with the SARS-CoV-2 spike protein.

The authors declare that there are no conflicts of interest. I declare the above statement as corresponding author and on behalf of other authors. Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. Journal of Virology 87, 8017-8028. https://doi.org/10. 1128/jvi.00998-13. Adrish, M., Chilimuri, S., Sun, H., Mantri, N., Yugay, A., & Zahid, M. (2020) . The association of renin-angiotensin-aldosterone system inhibitors with outcomes among a predominantly ethnic minority patient population hospitalized With COVID-19: The bronx experience. Cureus 12, e10217. https://doi.org/10.7759/cureus.10217. Agata, J., Ura, N., Yoshida, H., Shinshi, Y., Sasaki, H., Hyakkoku, M., ... Shimamoto, K. (2006) .

Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on

-converting enzyme

Atorvastatin induced increase in homologous angiotensin I converting enzyme (ACE2) mRNA is associated to decreased fibrosis and decreased left ventricular hypertrophy in a rat model of diabetic cardiomyopathy

PPAR gamma stimulation by rosiglitazone decreases blood pressure and renal apoptosis in a rat hypertension model secondary to aortic coarctation

Heparin and heparan sulfate block angiotensin II-induced hypertrophy in cultured neonatal rat cardiomyocytes. A possible role of intrinsic heparin-like molecules in regulation of cardiomyocyte hypertrophy

Aspirin induces platelet receptor shedding via ADAM17 (TACE)

Effect of hyperglycemia and rosiglitazone on renal and urinary neprilysin in db/db diabetic mice

Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases

Role of Wnt4/betacatenin, Ang II/TGFbeta, ACE2, NF-kappaB, and IL-18 in attenuating renal ischemia/ reperfusion-induced injury in rats treated with Vit D and pioglitazone

Effect of chronic beta blockers use on sepsis-related acute respiratory distress syndrome. A42. ARDS: RISK, TREATMENT, AND OUTCOMES, A1602-A1602

Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and tumor necrosis factor-alpha converting enzyme

The antiviral effects of Na,K-ATPase inhibition: A minireview

Ramipril in high risk patients with COVID-19

The effects of three reproductive hormones and cortisone on the replication of avian infectious bronchitis virus in vitro

Indomethacin has a potent antiviral activity against SARS coronavirus

Vitamin D depletion aggravates hypertension and target-organ damage

Circulating ACE2 in cardiovascular and kidney diseases

Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease

Vitamin D and survival in COVID-19 patients: A quasi-experimental study

Vitamin D supplementation associated to better survival in hospitalized frail elderly COVID-19 patients: The GERIA-COVID quasi-experimental study

Neither ACEIs nor ARBs are associated with respiratory distress or mortality in COVID-19 results of a prospective study on a hospital-based cohort

Protective effect of angiotensin II receptor blocker against oxidative stress and inflammation in an oral mucositis experimental model

The induction of C/EBPbeta contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney disease

Novel therapeutic approaches targeting the reninangiotensin system and associated peptides in hypertension and heart failure

Candesartan cilexetil protects from cardiac myosin induced cardiotoxicity via reduction of endoplasmic reticulum stress and apoptosis in rats: Involvement of ACE2-Ang (1-7)-mas axis

Serum levels of vitamin C and vitamin D in a cohort of critically Ill COVID-19 patients of a North American Community hospital intensive care unit in May 2020: A pilot study

Protective effects of aspirin and vitamin C against corn syrup consumption-induced cardiac damage through sirtuin-1 and HIF-1α pathway

Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin-angiotensin system in experimental arthritis

Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients

Telmisartan and captopril ameliorate pregabalin-induced heart failure in rats

Assessment of pregabalin-induced cardiotoxicity in rats: mechanistic role of angiotensin 1-7

Blood pressure lowering effect of Ficus deltoidea var kunstleri in spontaneously hypertensive rats: Possible involvement of renin-angiotensin-aldosterone system, endothelial function and anti-oxidant system

Effects of heparin treatments in vivo and in vitro on adrenal angiotensin II receptors and angiotensin IIinduced aldosterone production in rats

Angiotensin-converting enzyme 2 expression is not induced by the reninangiotensin system in the lung

Is the cardioprotective effect of the ACE2 activator diminazene aceturate more potent than the ACE inhibitor enalapril on acute myocardial infarction in rats?

Angiotensin converting enzyme inhibitor and angiotensin II receptor blocker use among outpatients diagnosed with COVID-19

Angiotensin II AT1 receptor alters ACE2 activity, eNOS expression and CD44-hyaluronan interaction in rats with hypertension and myocardial fibrosis

Effects of felodipine combined with puerarin on ACE2-Ang (1-7)-Mas axis in renovascular hypertensive rat

Vitamin D status and outcomes for hospitalised older patients with COVID-19

Corticosteroid therapy for patients with CoVID-19 pneumonia: A before-after study

Cell differentiation and aging is accompanied by depletion of the ACE2 protein

ACE-inhibitors and angiotensin-2 receptor blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust

Aldosterone effects on glomerular structure and function

Comparisons of Staphylococcus aureus infection and other outcomes between users of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers: Lessons for COVID-19 from a nationwide cohort study

Rosuvastatin use improves measures of coagulation in patients with venous thrombosis

Statin therapy in COVID-19 infection: Much more than a single pathway

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

The serum and glucocorticoid inducible kinases SGK1-3 stimulate the neutral amino acid transporter SLC6A19

Mechanism of human SIRT1 activation by resveratrol

ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma-implications for COVID-19

The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19. IJC Heart & Vasculature 31

Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens

Impact of comorbidities on SARS-CoV-2 viral entry-related genes

Vitamin D insufficiency and deficiency and mortality from respiratory diseases in a cohort of older adults: potential for limiting the death toll during and beyond the COVID-19 pandemic?

Prior routine use of non-steroidal anti-inflammatory drugs (NSAIDs) and important outcomes in hospitalised patients with COVID-19

Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression

Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: Implications for future therapeutic directions

Expression of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in the gut of patients With IBD

ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells

Chronic kidney disease: Cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition

Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition

Myocardial infarction increases ACE2 expression in rat and humans

Anti-inflammatory drugs and the reninangiotensin-aldosterone system: Current knowledge and potential effects on early SARS-CoV-2 infection

Spironolactone: An anti-androgenic and anti-hypertensive drug that may provide protection against the novel coronavirus (SARS-CoV-2) induced acute respiratory distress syndrome (ARDS) in COVID-19

Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: Systematic review and meta-analysis

Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis

Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype

Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation

Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: Effects on blood pressure control and mortality

Losartan and isoproterenol promote alterations in the local renin-angiotensin system of rat salivary glands

Immunohistochemical expression of intrarenal renin angiotensin system components in response to tempol in rats fed a high salt diet

Propofol increases angiotensin-converting enzyme 2 expression in human pulmonary artery endothelial cells

Angiotensin II-dependent hypertension requires cyclooxygenase 1-derived prostaglandin E2 and EP1 receptor signaling in the subfornical organ of the brain

Hijacking SARS-Cov-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on receptor binding region

Routine use of statins and increased mortality related to COVID-19 in inpatients with type 2 diabetes: Results from the CORONADO study

Simvastatin preconditioning confers neuroprotection against hypoxia-ischemia induced brain damage in neonatal rats via autophagy and silent information regulator 1 (SIRT1) activation

Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19

Central administration of TRV027 improves baroreflex sensitivity and vascular reactivity in spontaneously hypertensive rats

Angiotensin II, tissue factor and the thrombotic paradox of hypertension

Non-steroidal anti-inflammatory drugs and susceptibility to COVID-19

Prior diagnoses and medications as risk factors for COVID-19 in a Los Angeles Health System

ACE and ACE2: Their role to balance the expression of angiotensin II and angiotensin

Biochemical evaluation of the renin-angiotensin system: The good, bad, and absolute?

Mortality and pre-hospitalization use of renin-angiotensin system inhibitors in hypertensive COVID-19 patients

Losartan attenuates microvascular permeability in mechanical ventilator-induced lung injury in diabetic mice

In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds

Sini decoction ameliorates sepsis-induced acute lung injury via regulating ACE2-Ang (1-7)-Mas axis and inhibiting the MAPK signaling pathway

Interactions of renin-angiotensin system gene polymorphisms and antihypertensive effect of benazepril in Chinese population

BML-111, a lipoxin receptor agonist, protects against acute injury via regulating the renin angiotensin-aldosterone system

Lipoxin A4 attenuates LPS-induced acute lung injury via activation of the ACE2-Ang-(1-7)-Mas axis

Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension

The impact of renal denervation on the progression of heart failure in a canine model induced by right ventricular rapid pacing

Metformin attenuates hyperoxia-induced lung injury in neonatal rats by reducing the inflammatory response

Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening

Structure analysis of the receptor binding of 2019-nCoV

Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication

Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors

Citrus fruits are rich in flavonoids for immunoregulation and potential targeting ACE2. Preprints

Medical treatment of viral pneumonia including SARS in immunocompetent adult

Acute kidney injury in a case series of patients with confirmed COVID-19 (coronavirus disease 2019): Role of angiotensin-converting enzyme 2 and renin-angiotensin system blockade

Clinical and proteomic correlates of plasma ACE2 (angiotensin-converting enzyme 2) in human heart failure

ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome

Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19

Highfat diet-induced glucose dysregulation is independent of changes in islet ACE2 in mice

Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion

ARB/ACEI use and severe COVID-19: A nationwide case-control study

Murine coronavirus requires lipid rafts for virus entry and cell-cell fusion but not for virus release

Corticosteroid administration is associated with improved outcome in patients with severe acute respiratory syndrome coronavirus 2-related acute respiratory distress syndrome

Interaction between TGF-beta and ACE2-Ang-(1-7)-Mas pathway in high glucose-cultured NRK-52E cells

All-trans retinoic acid prevents development of cardiac remodeling in aortic banded rats by inhibiting the renin-angiotensin system

Aspirin use is associated with decreased mechanical ventilation, ICU admission, and in-hospital mortality in hospitalized patients with COVID-19

Renin-angiotensin system blockers and adverse outcomes of influenza and pneumonia: A Danish Cohort Study

Suppression of LPS-induced inflammatory responses by the hydroxyl groups of dexamethasone

Association between Angiotensin Blockade and Incidence of Influenza in the United Kingdom

Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress

SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2

Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro

Outcomes of COVID-19 hospitalized patients previously treated with reninangiotensin system inhibitors

Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia

Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes

Maternal corticosterone exposure in the mouse programs sex-specific renal adaptations in the renin-angiotensin-aldosterone system in 6-month offspring

Vitamin D receptor activation regulates microglia polarization and oxidative stress in spontaneously hypertensive rats and angiotensin II-exposed microglial cells: Role of renin-angiotensin system

Effects of heparin and enoxaparin on APP processing and Abeta production in primary cortical neurons from Tg2576 mice

The effects of reninangiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial

NSAIDs may increase the risk of thrombosis and acute renal failure in patients with COVID-19 infection

Metformin is a direct SIRT1-activating compound: Computational modeling and experimental validation

Tsantan Sumtang attenuated chronic hypoxia-induced right ventricular structure remodeling and fibrosis by equilibrating local ACE-AngII-AT1R/ACE2-Ang1-7-Mas axis in rat

Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients

The effects of ARBs, ACEis, and statins on Clinical outcomes of COVID-19 infection among nursing home residents

Inhibition of SIRT1 deacetylase and p53 activation uncouples the antiinflammatory and chemopreventive actions of NSAIDs

SARS-CoV-2 pathogenesis: Imbalance in the reninangiotensin system favors lung fibrosis

Angiotensin-converting enzyme I/D polymorphism and acute respiratory distress syndrome

Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism

Effect of propranolol on cardiac cytokine expression after myocardial infarction in rats

Embelin inhibits TNF-alpha converting enzyme and cancer cell metastasis: Molecular dynamics and experimental evidence

RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a metaanalysis of 19 studies

Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease

Heparin inhibits mesenteric vascular hypertrophy in angiotensin II-infusion hypertension in rats

High-density lipoprotein cholesterol as a factor affecting virus clearance in covid-19 patients

Antihypertensive activity of eucommia ulmoides oliv: Male flower extract in spontaneously hypertensive Rats. Evidence-based Complementary and Alternative Medicine

Superoxide anion mediates the L-selectin down-regulation induced by non-steroidal anti-inflammatory drugs in human neutrophils

Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

Effect of beta blockers on expression of interleukin-6 and C-reactive protein in patients with unstable angina pectoris

Reduced plasma angiotensin II levels are reversed by hydroxyurea treatment in mice with sickle cell disease

Simvastatin attenuates TNFalphainduced apoptosis in endothelial progenitor cells via the upregulation of SIRT1

Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity

Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study

Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality

Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2-and NF-κB-dependent pathways

Resveratrol and pterostilbene potently inhibit SARS-CoV-2 infection in vitro

Antihypertensive medication uses and serum ACE2 levels: ACEIs/ARBs treatment does not raise serum levels of ACE2

Soluble angiotensin-converting enzyme 2 in human heart failure: Relation with myocardial function and clinical outcomes

Detection of soluble angiotensin-converting enzyme 2 in heart failure: Insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system

Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study

Hypoxia induces dysregulation of local renin-angiotensin system in mouse Lewis lung carcinoma cells

Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women

Liraglutide enhances the activity of the ACE-2/Ang(1-7)/Mas receptor pathway in lungs of male pups from food-restricted mothers and prevents the reduction of SP-A

Effects of renal denervation on cardiac oxidative stress and local activity of the sympathetic nervous system and renin-angiotensin system in acute myocardial infracted dogs

Role of mineralocorticoid receptor and renin-angiotensin-aldosterone system in adipocyte dysfunction and obesity

Impact of glucocorticoid treatment in Sars-Cov-2 infection mortality: A retrospective controlled cohort study

Mechanisms by which angiotensinreceptor blockers increase ACE2 levels

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors

Treatment of resistant A/J mice with methylprednisolone (MP) results in loss of resistance to murine hepatitis strain 3 (MHV-3) and induction of macrophage procoagulant activity (PCA)

Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon

Effects of culture conditions and exposure to catabolic stimulators (IL-1 and retinoic acid) on the expression of matrix metalloproteinases (MMPs) and disintegrin metalloproteinases (ADAMs) by articular cartilage chondrocytes

Comparative effects of a novel angiotensin-converting enzyme inhibitor versus captopril on plasma angiotensins after myocardial infarction

Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality

An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect

The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis: A potential target for treating thrombotic diseases

Renin-angiotensin system blockers protect pancreatic islets against diet-induced obesity and insulin resistance in mice

The contribution of chymase-dependent formation of ANG II to cardiac dysfunction in metabolic syndrome of young rats: Roles of fructose and EETs

Aldosterone-induced kidney injury is mediated by NFkappaB activation

Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker

Alteration of the renin-angiotensin system in caerulein induced acute pancreatitis in the mouse

Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes

MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides

Regulation of ACE2 in cardiac myocytes and fibroblasts

4-Hydroxyisoleucine ameliorates an insulin resistant-like state in 3T3-L1 adipocytes by regulating TACE/TIMP3 expression. Drug Design

4-Hydroxyisoleucine improves insulin resistance in HepG2 cells by decreasing TNFalpha and regulating the expression of insulin signal transduction proteins

Risk of metformin in patients with type 2 diabetes with COVID-19: A preliminary retrospective report

Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents

COVID-19 in-hospital mortality and use of renin-angiotensin system blockers in geriatrics patients

The role of ACE2, angiotensin-(1-7) and Mas1 receptor axis in glucocorticoid-induced intrauterine growth restriction

A review of urinary angiotensin converting enzyme 2 in diabetes and diabetic nephropathy

Overexpression of the severe acute respiratory syndrome coronavirus-2 receptor, angiotensin-converting enzyme 2, in diabetic kidney disease: Implications for kidney injury in novel coronavirus disease 2019

ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 gene expression, and plasma ACE2 levels: A Mendelian randomization study

Long-term systemic angiotensin II type 1 receptor blockade regulates mRNA expression of dorsomedial medulla renin-angiotensin system components

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2

Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensinconverting enzyme 2

Rosiglitazone treatment restores renal responsiveness to atrial natriuretic peptide in rats with congestive heart failure

Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of Lselectin by non-steroidal anti-inflammatory drugs

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-Dimer and clinical severity of COVID-19 in hospitalized patients: A multicenter, observational study

Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths

Beneficial effects of losartan or telmisartan on the local hepatic renin-angiotensin system to counter obesity in an experimental model

Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus

Pixatimod (PG545), a clinical-stage heparan sulfate mimetic, is a potent inhibitor of the SARS-CoV-2 virus

The important role of lipid raft-mediated attachment in the infection of cultured cells by coronavirus infectious bronchitis virus beaudette strain

Coronavirus disease 2019 (COVID-19) and cardiovascular disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection

Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal INOS and angiotensin 2

Long-term therapy with ivabradine increases ace-2 activity in left ventricular myocardium of dogs with chronic heart failure

ACE2 is expressed in mouse adipocytes and

Cleavage of group 1 coronavirus spike proteins: How furin cleavage is traded off against heparan sulfate binding upon cell culture adaptation

Murine coronavirus with an extended host range uses heparan sulfate as an entry receptor

TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds

Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry

Antagonist of the type-1 ANG II receptor prevents against LPS-induced septic shock in rats

In vitro effects of propranolol on T helper type 1 cytokine profile in human leukemic T cells

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats

Losartan attenuates chronic cigarette smoke exposure-induced pulmonary arterial hypertension in rats: Possible involvement of angiotensin-converting enzyme-2

Chemical renal denervation-induced upregulation of the ACE2/Ang (1-7)/Mas axis attenuates blood pressure elevation in spontaneously hypertensive rats

Angiotensin-(1-7) treatment mitigates right ventricular fibrosis as a distinctive feature of diabetic cardiomyopathy

Binding of the SARS-CoV-2 spike protein to glycans

Imidapril inhibits right ventricular remodeling induced by low ambient temperature in broiler chickens

Imidapril provides a protective effect on pulmonary hypertension induced by low ambient temperature in broiler chickens

Osthole alleviates bleomycin-induced pulmonary fibrosis via modulating angiotensin-converting enzyme 2/angiotensin-(1-7) axis and decreasing inflammation responses in rats

Peroxisome proliferator-activated receptor alpha-dependent renoprotection of murine kidney by irbesartan

Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection

COX-1, and not COX-2 activity, regulates airway function: Relevance to aspirin-sensitive asthma

Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Proceedings

Vitamin D status in hospitalized patients with SARS-CoV-2 infection

Heparin enhances serpin inhibition of the cysteine protease cathepsin L

Increased ACE2 expression in the bronchial epithelium of COPD patients who are overweight

Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: Cohort study including 8.3 million people

Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction

Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus

Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor

Administration of nicotinamide riboside prevents oxidative stress and organ injury in sepsis

Dexamethasone in hospitalized patients with covid-19 -Preliminary report

Regulation of angiotensin II receptors beyond the classical pathway

Serum concentration of renin-angiotensin system components in association with ACE I/D polymorphism among hypertensive subjects in response to ACE inhibitor therapy

Preadmission antihypertensive drug use and sepsis outcome: Impact of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)

Aliskiren administration during early postnatal life sex-specifically alleviates hypertension programmed by maternal high fructose consumption

BML-111 equilibrated ACE-AngII-AT1R and ACE2-Ang-(1-7)-Mas axis to protect hepatic fibrosis in rats

Porcine epidemic diarrhea virus uses cell-surface heparan sulfate as an attachment factor

Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients

A review of therapeutic agents and Chinese herbal medicines against

Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors

Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease

The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension

Structure-based discovery of a novel angiotensinconverting enzyme 2 inhibitor

Heparin activation of serpins

Age and multimorbidity predict death among COVID-19 patients

Peroxisome proliferator-activated receptor-alpha stimulation by clofibrate favors an antioxidant and vasodilator environment in a stressed left ventricle

Blood pressure-independent effect of olmesartan on albuminuria in mice overexpressing renin

Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade

Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats

Angiotensin II reduces membranous angiotensin-converting enzyme 2 in pressurized human aortic endothelial cells

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Role of angiotensin-converting enzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition

Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy

Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors

Natural products and their derivatives against coronavirus: A review of the non-clinical and pre-clinical data

Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II Type 1 receptor blockade on vascular remodeling

Novel ACE2-IgG1 fusions with improved activity against SARS-CoV2

Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan

Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2

Cholesterol is important for the entry process of porcine deltacoronavirus

Association between nonsteroidal antiinflammatory drug use and adverse clinical outcomes among adults hospitalized with coronavirus 2019 in South Korea: A nationwide study

Role of the renin-angiotensin system in ventilator-induced lung injury: An in vivo study in a rat model

Differential effect of low dose thiazides on the Renin Angiotensin system in genetically hypertensive and normotensive rats

Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats

Sex-specific modulation of blood pressure and the renin-angiotensin system by ACE (angiotensin-converting enzyme) 2

ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia

Cardioprotective effects of granulocyte colony-stimulating factor in angiotensin II-induced cardiac remodelling

Hypertension and renin-angiotensin system blockers are not associated with expression of Angiotensin Converting Enzyme 2 (ACE2) in the kidney

Tanshinones, critical pharmacological components in Salvia miltiorrhiza

ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production

Vitamin D supplementation to prevent acute respiratory infections: Systematic review and meta-analysis of aggregate data from randomised controlled trials

Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis

Green tea and Spirulina extracts inhibit SARS, MERS, and SARS-2 spike pseudotyped virus entry in vitro

Angiotensin converting enzyme versus angiotensin converting enzyme-2 selectivity of MLN-4760 and DX600 in human and murine bone marrow-derived cells

Inhibitors of the renin-angiotensin-aldosterone system and COVID-19 in critically ill elderly patients

Altered pathogenesis of porcine respiratory coronavirus in pigs due to immunosuppressive effects of dexamethasone: Implications for corticosteroid use in treatment of severe acute respiratory syndrome coronavirus

Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: A nationwide population-based cohort study

Aspirin targets SIRT1 and AMPK to induce senescence of colorectal carcinoma cells

Esculetin attenuates alterations in Ang II and acetylcholine mediated vascular reactivity associated with hyperinsulinemia and hyperglycemia

Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2

Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers: A comparison of outcomes in patients with COVID-19

Aspirin may promote mitochondrial biogenesis via the production of hydrogen peroxide and the induction of Sirtuin1/PGC-1α genes

Update alert: Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults

International union of basic and clinical pharmacology. XCIX. Angiotensin receptors: Interpreters of pathophysiological angiotensinergic stimuli

An hACE2 peptide mimic blocks SARS-CoV-2 pulmonary cell infection

Effects of spironolactone and eprosartan on cardiac remodeling and angiotensinconverting enzyme isoforms in rats with experimental heart failure

Natural compounds inhibiting the replication of Porcine reproductive and respiratory syndrome virus

AT2 receptors in cardiovascular and renal diseases

Lipid-lowering therapy and reninangiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic

Improvement of endothelial function by pitavastatin: A meta-analysis

SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels

Mineralocorticoid receptor blocker increases angiotensinconverting enzyme 2 activity in congestive heart failure patients

Airway expression of SARS-CoV-2 receptor, ACE2, and proteases, TMPRSS2 and furin, in severe asthma

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Angiotensin converting enzyme inhibitors do not increase the risk of poor outcomes in COVID-19 disease. A multi-centre observational study

Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with coronavirus disease-19

Azilsartan causes natriuresis due to its sympatholytic action in kidney disease

Expression of genes of the cardiac and renal renin-angiotensin systems in preterm piglets: Is this system a suitable target for therapeutic intervention?

The protective effect of resveratrol on vascular aging by modulation of the renin-angiotensin system

Effect of reninangiotensin system blockage in patients with acute respiratory distress syndrome: A retrospective case control study

Compliance of antihypertensive medication and risk of coronavirus disease 2019: A cohort study using big data from the korean national health insurance service

Regulation of organelle function by metformin

Clinical outcomes from COVID-19 following use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in South Korea: A nationwide study

Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells

Plasma angiotensin peptide profiling and ACE (angiotensin-converting enzyme)-2 activity in COVID-19 patients treated with pharmacological blockers of the renin-angiotensin system

Biological sex impacts COVID-19 outcomes

Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats

Protective angiotensin type 2 receptors in the brain and hypertension

Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells

Impact of antihypertensive agents on clinical course and in-hospital mortality: Analysis of 169 hypertensive patients hospitalized for COVID-19

Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway

Spironolactone rescues renal dysfunction in obstructive jaundice rats by upregulating ACE2 expression

Regulation of secretases by all-trans-retinoic acid

Increased incidence, morbidity, and mortality in human coronavirus NL63 associated with ACE inhibitor therapy and implication in SARS

Age, inflammation and disease location are critical determinants of intestinal expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in inflammatory bowel disease

Trilogy of ACE2: A peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Prediction of off-target effects on angiotensinconverting enzyme 2

Determinants of circulating angiotensinconverting enzyme 2 protein levels in the general population

Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro

Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: Results of the ACE-CoV study

Continued in-hospital ACE inhibitor and ARB Use in hypertensive COVID-19 patients is associated with positive clinical outcomes

Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)

Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans

Effects of exendin-4 on the intrarenal renin-angiotensin system and interstitial fibrosis in unilateral ureteral obstruction mice: Exendin-4 and unilateral ureteral obstruction

Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease

ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs

Robust ACE2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ACE inhibitors or angiotensin receptor blockers

Effects of reninangiotensin system blockers on the risk and outcomes of SARS-CoV-2 infection in patients with hypertension

Potential role of statins in COVID-19

Use of non-steroidal anti-inflammatory drugs correlates with the risk of venous thromboembolism in knee osteoarthritis patients: A UK population-based casecontrol study

Beneficial effects of ethanol extracts of Red Liriope platyphylla on vascular dysfunction in the aorta of spontaneously hypertensive rats

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

Renal ACE2 expression in human kidney disease

Combined antihypertensive therapies that increase expression of cardioprotective biomarkers associated with the renin-angiotensin and Kallikrein-Kinin systems

Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-alpha in myocardial infarction-induced cardiac fibrosis

Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection

Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19

Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle

Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China

Association between circulating angiotensin-converting enzyme 2 and cardiac remodeling in hypertensive patients

Fugan Wan alleviates hepatic fibrosis by inhibiting ACE/Ang II/AT-1R signaling pathway and enhancing ACE2/Ang 1-7/Mas signaling pathway in hepatic fibrosis rat models

Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2

Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2

Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis

Valsartan attenuates intimal hyperplasia in balloon-injured rat aortic arteries through modulating the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis

SARS-CoV-2 and three related coronaviruses utilize multiple ACE2 orthologs and are potently blocked by an improved ACE2-Ig

Angiotensinconverting enzyme inhibition attenuates lipopolysaccharide-induced lung injury by regulating the balance between angiotensin-converting enzyme and angiotensinconverting enzyme 2 and inhibiting mitogen-activated protein kinase activation

Effects of rosuvastatin on expression of angiotensin-converting enzyme 2 after vascular balloon injury in rats

Synthesis of stilbene derivatives with inhibition of SARS coronavirus replication

Association between renin-angiotensin system inhibitors and COVID-19 complications

Atorvastatin attenuates plaque vulnerability by downregulation of EMMPRIN expression via COX-2/ PGE2 pathway

Urinary angiotensin converting enzyme 2 increases in patients with type 2 diabetic mellitus

Egg white-derived tripeptide IRW (Ile-Arg-Trp) is an activator of angiotensin converting enzyme 2

Egg white-derived antihypertensive peptide IRW (Ile-Arg-Trp) reduces blood pressure in spontaneously hypertensive rats via the ACE2/Ang (1-7)/Mas receptor axis

Cyclooxygenase mediates cardioprotection of angiotensin-(1-7) against ischemia/reperfusion-induced injury through the inhibition of oxidative stress

Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation

Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease

Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein-ACE2 interaction

Calcitriol regulates angiotensin-converting enzyme and angiotensin converting-enzyme 2 in diabetic kidney disease

Effective inhibition of MERS-CoV infection by resveratrol

Ginsenoside Rg3 attenuates angiotensin II-mediated renal injury in rats and mice by upregulating angiotensin-converting enzyme 2 in the renal tissue

Sini decoction alleviates E. coli induced acute lung injury in mice via equilibrating ACE-AngII-AT1R and ACE2-Ang-(1-7)-Mas axis

Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome

SARS-CoV-2 spike protein binds heparan sulfate in a length-and sequence-dependent manner

Protective effect of RA on myocardial infarction-induced cardiac fibrosis via AT1R/p38 MAPK pathway signaling and modulation of the ACE2/ACE ratio

Renal denervation findings on cardiac and renal fibrosis in rats with isoproterenol induced cardiomyopathy

Angiotensin-converting enzyme (ACE and ACE2) imbalance correlates with the severity of cerulein-induced acute pancreatitis in mice

Ulinastatin activates the renin-angiotensin system to ameliorate the pathophysiology of severe acute pancreatitis

Quercetin and its metabolites inhibit recombinant human angiotensin-converting enzyme 2 (ACE2) activity

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice

Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population

High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity

Early postnatal treatment with soluble epoxide hydrolase inhibitor or 15-deoxy-Delta (12,14)-prostagandin J2 prevents prenatal dexamethasone and postnatal high saturated fat diet induced programmed hypertension in adult rat offspring

Lipid rafts are involved in SARS-CoV entry into Vero E6 cells

Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study

Oxidative stress causes imbalance of renal renin angiotensin system (RAS) components and hypertension in obese Zucker rats

Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension

Effects of taurine on blood index of hypothalamic pituitary adrenal (HPA) axis of stress-induced hypertensive rat

Angiotensinconverting enzyme 2 overexpression protects against doxorubicin-induced cardiomyopathy by multiple mechanisms in rats

Angiotensin-(1-7)/Mas signaling inhibits lipopolysaccharide-induced ADAM17 shedding activity and apoptosis in alveolar epithelial cells

Interaction between age and vitamin D deficiency in severe COVID-19 infection

Vitamin D supplementation alters the expression of genes associated with hypertension and did not induce DNA damage in rats

Heparan sulfate is a selective attachment factor for the avian coronavirus infectious bronchitis virus Beaudette

Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region

Egg ovotransferrin-derived ACE inhibitory peptide IRW increases ACE2 but decreases proinflammatory genes expression in mesenteric artery of spontaneously hypertensive rats

A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19

Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy

Sitagliptin favorably modulates immune-relevant pathways in human beta cells

Renin-angiotensin-aldosterone system blockers and the risk of covid-19

Natural product-derived phytochemicals as potential agents against coronaviruses: A review

Klotho and PPAR gamma activation mediate the renoprotective effect of losartan in the 5/6 nephrectomy model

The cholesterol metabolite 27-hydroxycholesterol inhibits SARS-CoV-2 and is markedly decreased in COVID-19 patients

Urinary angiotensin converting enzyme 2 is strongly related to urinary nephrin in type 2 diabetes patients

Antenatal betamethasone exposure is associated with lower ANG-(1-7) and increased ACE in the CSF of adult sheep

Bacterial modification of the host glycosaminoglycan heparan sulfate modulates SARS-CoV-2 infectivity

Effect of statin therapy on Sars-Cov-2 infection-related mortality in hospitalized patients

Sex-dependent effects of antenatal glucocorticoids on insulin sensitivity in adult sheep: Role of the adipose tissue renin angiotensin system

Association between insertion/ deletion polymorphism in angiotensin-converting enzyme gene and acute lung injury/acute respiratory distress syndrome: A meta-analysis

Effects of carvedilol on plasma levels of interleukin-6 and tumor necrosis factor-alpha in nine patients with dilated cardiomyopathy

The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells

Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: A retrospective cohort study

Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE)

Simvastatin in the acute respiratory distress syndrome

Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus

Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19

Membrane cholesterol modulates oligomeric status and peptide-membrane interaction of severe acute respiratory syndrome coronavirus fusion peptide

Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19)

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension

The angiotensinconverting enzyme 2/angiotensin (1-7)/Mas axis protects against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived ROS-mediated RhoA/Rho kinase pathway

Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis protects against lung fibrosis by inhibiting the MAPK/NF-kappaB pathway

Low plasma 25(OH) vitamin D3 level is associated with increased risk of COVID-19 infection: An Israeli population-based study

Perindopril ameliorates experimental Alzheimer's disease progression: Role of amyloid beta degradation, central estrogen receptor and hyperlipidemic-lipid raft signaling

Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection

A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists

G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor

Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells

Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis

Inhaled corticosteroids downregulate SARS-CoV-2-related gene expression in COPD: Results from a RCT

SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors

Effects of Pravastatin on Type 1 Diabetic Rat Heart with or without Blood Glycemic Control

Urinary angiotensin-converting enzyme 2 in patients with CKD

Pleiotropic effects of statins: untapped potential for statin pharmacotherapy

Calcitriol, the active form of vitamin D, is a promising candidate for COVID-19 prophylaxis

Impact of late administration of corticosteroids in COVID-19 ARDS

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2

Expression of receptors for SARS-CoV-2 in the gut of patients with inflammatory bowel disease

Enalapril improves obesity associated liver injury ameliorating systemic metabolic markers by modulating Angiotensin Converting Enzymes ACE/ACE2 expression in high-fat feed mice

Renin-angiotensin system blockers and susceptibility to COVID-19: A multinational open science cohort study

Resveratrol inhibits growth of experimental abdominal aortic aneurysm associated with upregulation of angiotensin-converting enzyme 2

Paricalcitol inhibits aldosterone-induced proinflammatory factors by modulating epidermal growth factor receptor pathway in cultured tubular epithelial cells

Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes

Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factoralpha

Vitamin D insufficiency as a potential culprit in critical COVID-19 patients

Heparin inhibits cellular invasion by SARS-CoV-2: Structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin

Reduced isoproterenol-induced renin-angiotensin changes and extracellular matrix deposition in hearts of TGR(A1-7)3292 rats

Activation of alpha-secretase by curcumin-aminoacid conjugates

Impact of treatment with renin-angiotensin system inhibitors on clinical outcomes in hypertensive patients hospitalized with COVID-19

HNF4alpha dysfunction as a molecular rational for cyclosporine induced hypertension

beta-blocker therapy and risk of chronic obstructive pulmonary disease -A danish nationwide study of 1.3 million individuals

Effect of oral beta-blocker on short and long-term mortality in patients with acute respiratory failure: Results from the BASEL-II-ICU study

Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat

Rho kinase inhibition activates the homologous angiotensin-converting enzymeangiotensin-(1-9) axis in experimental hypertension

Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade

ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II

Cross talk between angiotensin-(1-7)/Mas axis and sirtuins in adipose tissue and metabolism of high-fat feed mice

Aliskiren attenuates the inflammatory response and wound healing process in diabetic mice with periodontal disease

Effects of rosuvastatin and amlodipine on reninangiotensin system of kidney in NOS inhibition and salt diet induced hypertension

Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: A prospective controlled study

Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arteriosclerosis, Thrombosis, and Vascular Biology

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Long-term ACE inhibitor/ARB use is associated with severe renal dysfunction and acute kidney injury in patients with severe COVID-19: Results from a referral center cohort in the Northeast of France

Role of ADAM17 in kidney disease

Antecedent administration of angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists and survival after hospitalization for COVID-19 syndrome

Angiotensin-converting enzyme 2 A1075G polymorphism is associated with survival in an acute coronary syndromes cohort

FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/ angiotensin-(1-7) axis in mice

Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalised with COVID-19 are associated with greater disease severity

Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats. Drug Design

Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: A randomized clinical trial

Synergistic inhibitory effect of angiotensin-converting enzyme inhibitor and heparin on intimal hyperplasia after rat aorta injury

Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases

Unfractionated heparin potently inhibits the binding of SARS-CoV-2 spike protein to a human cell line

ACE2-independent interaction of SARS-CoV-2 spike protein to human epithelial cells can be inhibited by unfractionated heparin

Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ ADAM-17: A positive feedback mechanism in the RAS

Counter-regulatory renin-angiotensin system in cardiovascular disease

Speciesspecific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays

Changes in trophoblasts gene expression in response to perchlorate exposition

Impact of ACE2 deficiency and oxidative stress on cerebrovascular function with aging

Susceptibility of the elderly to SARS-CoV-2 infection: ACE-2 overexpression, shedding, and antibody-dependent enhancement

Brazil) 75, e1912

Relationship to demographic features and corticosteroids

ACE2 Expression is increased in the lungs of patients with comorbidities associated with severe COVID-19

Antihypertensive drugs in COVID-19 infection

Effect of statin therapy on arterial wall inflammation based on 18F-FDG PET/CT: A systematic review and meta-analysis of interventional studies

Classical drug digitoxin inhibits influenza cytokine storm, with implications for covid-19 therapy

Reduced expression of COVID-19 host receptor, ACE2 is associated with small bowel inflammation, more severe disease, and response to anti-TNF therapy in Crohn′s disease

Intravenous Vitamin C attenuates hemorrhagic shock-related renal injury through the induction of SIRT1 in rats

Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II

Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats

alpha-Lipoic acid reduces neurogenic hypertension by blunting oxidative stress-mediated increase in ADAM17

Cholesterol in relation to COVID-19: Should we care about It?

Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors

Angiotensin-(1-7) augments endothelium-dependent relaxations of porcine coronary arteries to bradykinin by inhibiting angiotensin-converting enzyme 1

Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome

Renin-angiotensin-aldosterone system blockers are not associated with coronavirus disease 2019 (COVID-19) hospitalization: Study of 1,439 UK Biobank cases

Plasma ACE2 activity predicts mortality in aortic stenosis and is associated with severe myocardial fibrosis

Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease

Metformin reverses established lung fibrosis in a bleomycin model

Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: A mendelian randomization analysis highlights tentative relevance of diabetes-related traits

Contribution of alpha -and beta -Adrenergic mechanisms to the development of pulmonary edema. Scientifica (Cairo) 2012, 829504

Short term, high-dose vitamin D supplementation for COVID-19 disease: A randomised, placebo-controlled, study (SHADE study)

Circulating angiotensin peptides levels in Acute Respiratory Distress Syndrome correlate with clinical outcomes: A pilot study

Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease

Low total cholesterol blood level is correlated with pulmonary severity in COVID-19 critical ill patients

Renin-angiotensin-aldosterone system inhibitors and risk of covid-19

The kallikrein-kinin system as a regulator of cardiovascular and renal function

Effect of glucocorticoid on piglet jejunal mucosa during acute viral enteritis

Circulating activities of angiotensin-converting enzyme, its homolog, angiotensinconverting enzyme 2, and neprilysin in a family study

Treatment of sepsis-induced acquired protein C deficiency reverses Angiotensin-converting enzyme-2 inhibition and decreases pulmonary inflammatory response

Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria

Angiotensin-converting enzyme 2 activity in patients with chronic kidney disease

Statins: Could an old friend help the fight against COVID-19?

Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: A retrospective cohort study

Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)

Direct renin inhibition in a rat model of chronic allograft injury

Interactive effects of apelin, renin-angiotensin system and nitric oxide in treatment of obesity-induced type 2 diabetes mellitus in male albino rats

Statin use and in-hospital mortality in diabetics with COVID-19

Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice

Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors

Rosiglitazone, a ligand to PPARgamma, improves blood pressure and vascular function through renin-angiotensin system regulation

The ACE2/angiotensin-(1-7)/MAS axis of the reninangiotensin system: Focus on angiotensin

Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? Data from centers of Southern Italy

Downregulation of monocytic differentiation via modulation of CD147 by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

Eplerenone inhibits tumour necrosis factor alpha shedding process by tumour necrosis factor alpha converting enzyme in monocytes from patients with congestive heart failure

Attenuation of chronic antiviral T-cell responses through constitutive COX2-dependent prostanoid synthesis by lymph node fibroblasts

Non-steroidal anti-inflammatory drug use and risk of venous thromboembolism

Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?

Cardiovascular interactions between losartan and fructose in mice

Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19

Geranium and lemon essential oils and their active compounds downregulate angiotensin-converting enzyme 2 (ACE2), a SARS-CoV-2 spike receptor-binding domain

Ang II (angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent

Alterations in circulatory and renal angiotensin-converting enzyme and angiotensin-converting enzyme 2 in fetal programmed hypertension

Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure

Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin

Involvement of TACE in colon inflammation: A novel mechanism of regulation via SIRT-1 activation

Overexpression of catalase prevents hypertension and tubulointerstitial fibrosis and normalization of renal angiotensin-converting enzyme-2 expression in Akita mice

Osthole protects lipopolysaccharide-induced acute lung injury in mice by preventing downregulation of angiotensin-converting enzyme 2

SIRT1 increases cardiomyocyte binucleation in the heart development

The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts

Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2

Beneficial effects of the activation of the angiotensin-(1-7) MAS receptor in a murine model of adriamycin-induced nephropathy

Longterm outcome of short-course high-dose glucocorticoids for SARS: A 17-year follow-up in SARS survivors

Valproic acid in prevention and treatment of COVID-19

Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg (9) bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration

CYP4A2-induced hypertension is 20-hydroxyeicosatetraenoic acid-and angiotensin II-dependent

Effects of angiotensin receptor blockers (ARBs) on in-hospital outcomes of patients with hypertension and confirmed or clinically suspected COVID-19

Circulating angiotensin-converting enzyme 2 activity in kidney transplantation: A longitudinal pilot study

Localization of ACE2 in the renal vasculature: Amplification by angiotensin II type 1 receptor blockade using telmisartan

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19

Daily exercise training protects against albuminuria and angiotensin converting enzyme 2 shedding in db/db diabetic mice

Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Infection in South Korea. Hypertension, 0

Angiotensin-converting enzyme 2 attenuates oxidative stress and VSMC proliferation via the JAK2/STAT3/ SOCS3 and profilin-1/MAPK signaling pathways

Statin use is associated with decreased risk of invasive mechanical ventilation in COVID-19 patients: A preliminary study

Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications

Angiotensin II type 1 receptor blockade restores angiotensin-(1-7)-induced coronary vasodilation in hypertrophic rat hearts

Risks of ACE inhibitor and ARB usage in COVID-19: Evaluating the evidence

Inhibition of TNF in the brain reverses alterations in RAS components and attenuates angiotensin II-induced hypertension

Brain-targeted angiotensinconverting enzyme 2 overexpression attenuates neurogenic hypertension by inhibiting cyclooxygenase-mediated inflammation

Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome

SARS: Systematic review of treatment effects

Both aldosterone and spironolactone can modulate the intracellular ACE/ANG II/AT1 and ACE2/ANG

/MAS receptor axes in human mesangial cells

FDA approved calcium channel blockers inhibit SARS CoV 2 infectivity in epithelial lung cells

SIRT1 as a therapeutic target in diabetic complications

Angiotensin-(1-7) inhibits angiotensin IIstimulated phosphorylation of MAP kinases in proximal tubular cells

Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2 related disease

RAAS blockade, kidney disease, and expression of ACE2, the entry receptor for SARS-CoV-2, in kidney epithelial and endothelial cells

Role of oxidative stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) infection: A review

Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE-2/ANG 1-7/Mas receptor cascade

Telmisartan acts through the modulation of ACE-2/ANG 1-7/ mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis

Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis

Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1-7 mas receptor

Anti-fibrotic mechanisms of angiotensin AT(2) -receptor stimulation

Cationic nanoparticles directly bind angiotensin-converting enzyme 2 and induce acute lung injury in mice

Chronic use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers is high among intensive care unit patients with non-COVID-19 sepsis but carries a moderately increased risk of death

Severe acute respiratory syndrome: Report of treatment and outcome after a major outbreak

Influence of atorvastatin on angiotensin I metabolism in resting and TNFalpha -activated rat vascular smooth muscle cells

Cardioprotective effect of ulmus wallichiana planchon in beta-adrenergic agonist induced cardiac hypertrophy

Acute kidney injury in COVID-19 pneumonia: A Single-Center Experience in Bahrain

Targeting arachidonic acid pathway to prevent programmed hypertension in maternal fructose-fed male adult rat offspring

Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean

Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats

Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats

Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). Nutrition 79-80

Statin use is associated with lower disease severity in COVID-19 infection

Lipoprotein concentrations over time in the intensive care unit COVID-19 patients: Results from the ApoCOVID study

Effective inhibition of SARS-CoV-2 entry by heparin and enoxaparin derivatives

Olmesartan inhibits cardiac hypertrophy in mice overexpressing renin independently of blood pressure: Its beneficial effects on ACE2/Ang(1-7)/Mas axis and NADPH oxidase expression

Soluble epoxide hydrolase plays a vital role in angiotensin II-induced lung injury in mice

Vitamin D supplementation could potentially reduce risk of COVID-19 infections and deaths

Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-19

Gemcitabine and cisplatin for treatment of lung cancer in vitro and vivo

The versatile heparin in COVID-19

Investigation into SARS-CoV-2 resistance of compounds in garlic essential oil

Resveratrol ameliorates maternal and post-weaning high-fat diet-induced nonalcoholic fatty liver disease via renin-angiotensin system

ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes

Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy

Modulation of the expression of genes related to the system of amyloid-beta metabolism in the brain as a novel mechanism of ceftriaxone neuroprotective properties

Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: Role of epigenetic histone modifications

A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

Preferential recognition and antagonism of SARS-CoV-2 spike glycoprotein binding to 3-O -sulfated heparan sulfate

Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C-and N-domain blockade

Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency

Unfractionated heparin inhibits live wild-type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations

Depletion of cellular cholesterol and lipid rafts increases shedding of CD30

Renin-angiotensin-aldosterone system inhibitors and risk of death in patients hospitalised with COVID-19: A retrospective italian cohort study of 43,000 patients

Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: A randomised, doubleblind, placebo-controlled, mechanistic study

Monocytic angiotensin-converting enzyme 2 relates to atherosclerosis in patients with chronic kidney disease

Rosuvastatin for sepsis-associated acute respiratory distress syndrome

Metformin attenuates ventilator-induced lung injury

Regulation of the expression of angiotensin-converting enzyme 2 by polyunsaturated fatty acids in porcine adipocytes

Tempol ameliorates murine viral encephalomyelitis by preserving the blood-brain barrier, reducing viral load, and lessening inflammation

Severe acute respiratory syndrome: Clinical outcome and prognostic correlates

ACE2 cell biology, regulation, and physiological functions

Cell cycle dependence of ACE-2 explains downregulation in idiopathic pulmonary fibrosis

Potentiation of angiotensin II action by corticosteroids in vascular tissue

Nonsteroidal anti-inflammatory drugs and risk of venous thromboembolism: A systematic review and meta-analysis

Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren

Circulating ACE2 activity correlates with cardiovascular disease development

New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: Circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure

Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats

Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive rats

Cardiovascular risk of nonsteroidal antiinflammatory drugs: An under-recognized public health issue

Eplerenone implantation improved adipose dysfunction averting RAAS activation and cell division. Front Endocrinol (Lausanne) 11, 223

Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition

Coronaviridae and SARS-associated coronavirus strain HSR1

The efficacy of the mineralcorticoid receptor antagonist canrenone in COVID-19 patients

Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase

Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia

The plasmatic aldosterone and C-reactive protein levels, and the severity of Covid-19: The Dyhor-19 study

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Alpha-1 adrenergic receptor antagonists for preventing acute respiratory distress syndrome and death from cytokine storm syndrome

Risks related to the use of non-steroidal anti-inflammatory drugs in communityacquired pneumonia in adult and pediatric patients

Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors

Stilbene-based natural compounds as promising drug candidates against COVID-19

Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation

Angiotensin converting enzyme 2 activity and human atrial fibrillation: Increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling

Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy

Sildenafil protects against myocardial ischemia-reperfusion injury following cardiac arrest in a porcine model: possible role of the renin-angiotensin system

Enalapril protects against myocardial ischemia/reperfusion injury in a swine model of cardiac arrest and resuscitation

Low highdensity lipoprotein level is correlated with the severity of COVID-19 patients: An observational study

ADAM17 participates in the protective effect of paeoniflorin on mouse brain microvascular endothelial cells

Astragaloside III activates TACE/ADAM17-dependent anti-inflammatory and growth factor signaling in endothelial cells in a p38-dependent fashion

The role of high cholesterol in agerelated COVID19 lethality

The ACE2-angiotensin-(1-7)-Mas axis protects against pancreatic cell damage in cell culture

Cholesterol enhances amyloid beta deposition in mouse retina by modulating the activities of Abeta-regulating enzymes in retinal pigment epithelial cells

SARS-CoV-2 invades host cells via a novel route: CD147-spike protein

Angiotensin-converting enzyme 2 attenuates bleomycin-induced lung fibrosis in mice

Long-term renal sympathetic denervation ameliorates renal fibrosis and delays the onset of hypertension in spontaneously hypertensive rats

Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus

Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol

Regulatory effects of a pea-derived peptide Leu-Arg-Trp (LRW) on dysfunction of rat aortic vascular smooth muscle cells against angiotensin II stimulation

The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice

A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia

Cardioprotective effects of qishenyiqi mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin-converting enzyme 2. Evidence-based Complementary and Alternative Medicine

Renal denervation improves vascular endothelial dysfunction by inducing autophagy via AMPK/mTOR signaling activation in a rat model of type 2 diabetes mellitus with insulin resistance

Severe acute pancreatitis is associated with upregulation of the ACE2-angiotensin-(1-7)-Mas axis and promotes increased circulating angiotensin

A comprehensive investigation of the mRNA and protein level of ACE2, the putative receptor of SARS-CoV-2, in human tissues and blood cells

Tanshinone IIA attenuates paraquatinduced acute lung injury by modulating angiotensinconverting enzyme 2/angiotensin(17) in rats

Fasudil alleviated hypoxiainduced pulmonary hypertension by stabilizing the expression of angiotensin-(1-7) in rats

Naringenin ameliorates renovascular hypertensive renal damage by normalizing the balance of reninangiotensin system components in rats

Small molecule therapeutics for COVID-19: Repurposing of inhaled furosemide

A retrospective study from 2 centers in China on the effects of continued use of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers in patients with hypertension and COVID-19

Heparan sulfate is a binding molecule but not a receptor for CEACAM1-independent infection of murine coronavirus

Cholesterol metabolism -Impact for SARS-CoV-2 infection prognosis, entry, and antiviral therapies

Baicalin attenuates angiotensin II-induced endothelial dysfunction

GW25-e4430 ibuprofen attenuates cardiac fibrosis via restoring the imbalance of ACE and ACE2 in diabetic rat

Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus

Oxidative stress and glomerular filtration barrier injury: Role of the renin-angiotensin system in the Ren2 transgenic rat

Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19

Converging pathways in pulmonary fibrosis and Covid-19 -The fibrotic link to disease severity

Repositioning of the beta-blocker carvedilol as a novel autophagy inducer that inhibits the NLRP3 inflammasome

Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Effects of renin-angiotensin inhibition on ACE2 and TMPRSS2 expression: Insights into COVID-19

GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies

Tanshinone IIA attenuates bleomycin-induced pulmonary fibrosis via modulating angiotensin-converting enzyme 2/ angiotensin-(1-7) axis in rats

Altered lipid metabolism in recovered SARS patients twelve years after infection

Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats

Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the chinese center for disease control and prevention

Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease

Kidney and lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: Implications for COVID-19

Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice

Brain angiotensinconverting enzyme type 2 shedding contributes to the development of neurogenic hypertension

Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels

Captopril improves postresuscitation hemodynamics protective against pulmonary embolism by activating the ACE2/Ang-(1-7)/Mas axis

Association between ACE2/ACE balance and pneumocyte apoptosis in a porcine model of acute pulmonary thromboembolism with cardiac arrest

Imbalance of angiotensin-converting enzymes affects myocardial apoptosis during cardiac arrest induced by acute pulmonary embolism in a porcine model

Angiotensin II regulates ACE and ACE2 in neurons through p38 mitogen-activated protein kinase and extracellular signalregulated kinase 1/2 signaling

Heparin inhibits angiotensin II-induced vasoconstriction on isolated mouse mesenteric resistance arteries through Rho-A-and PKA-dependent pathways

Use of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: A retrospective analysis

A Disintegrin and metalloprotease 17 in the cardiovascular and central nervous systems

Clinical relevance and role of neuronal AT1 receptors in ADAM17-mediated ACE2 shedding in neurogenic hypertension

Vitamin D alleviates lipopolysaccharideinduced acute lung injury via regulation of the reninangiotensin system

Effects of a novel curcumin derivative on the functions of kidney in streptozotocin-induced type 2 diabetic rats

RhoA-Rho associated kinase signaling leads to renin-angiotensin system imbalance and angiotensin converting enzyme 2 has a protective role in acute pulmonary embolism

Glucocorticoid modulates angiotensin II receptor expression patterns and protects the heart from ischemia and reperfusion injury

Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: A retrospective cohort study

Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes

Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells

Nucleocapsid protein of SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factor-kappa B and CCAAT/enhancer binding protein

Identification of anti-viral activity of the cardenolides, Na(+)/K(+)-ATPase inhibitors, against porcine transmissible gastroenteritis virus

The cardenolide ouabain suppresses coronaviral replication via augmenting a Na(+)/K(+)-ATPase-dependent PI3K_PDK1 axis signaling

Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: A single-center retrospective study

Dietary 25-hydroxyvitamin D3 supplementation alleviates porcine epidemic diarrhea virus infection by improving intestinal structure and immune response in weaned pigs

Liraglutide attenuates non-alcoholic fatty liver disease in mice by regulating the local renin-angiotensin system

Angiotensinconverting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury

The utility of native MS for understanding the mechanism of action of repurposed therapeutics in COVID-19: Heparin as a disruptor of the SARS-CoV-2 interaction with its host cell receptor

The effect of corticosteroid treatment on patients with coronavirus infection: A systematic review and metaanalysis

Effects of enalapril on the expression of cardiac angiotensin-converting enzyme and angiotensin-converting enzyme 2 in spontaneously hypertensive rats

Losartan attenuates ventilator-induced lung injury

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Time-course analysis reveals that corticosteroids resuscitate diminished CD8+ T cells in COVID-19: A retrospective cohort study

Does Serum vitamin D level affect COVID-19 infection and its severity?-A case-control study

Murine recombinant angiotensin-converting enzyme 2: Effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2

Telmisartan attenuates hepatic fibrosis in bile duct-ligated rats

Angiotensin receptor blocker irbesartan reduces stressinduced intestinal inflammation via AT1a signaling and ACE2-dependent mechanism in mice

Prenatal dexamethasone and postnatal high-fat diet have a synergistic effect of elevating blood pressure through a distinct programming mechanism of systemic and adipose renin-angiotensin systems

Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2

In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension

Activation of reninangiotensin-aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats

Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin

Potential effects of curcumin in the treatment of COVID-19 infection

Immune modulatory effects of statins

Impact of curcumin on sirtuins: A review

DKK3 overexpression attenuates cardiac hypertrophy and fibrosis in an angiotensinperfused animal model by regulating the ADAM17/ACE2 and GSK-3beta/beta-catenin pathways

Dynamic variation of RAS on silicotic fibrosis pathogenesis in rats

Recombinant human ACE2: Acing out angiotensin II in ARDS therapy

Endothelin-1 downregulates angiotensinconverting enzyme-2 expression in human bronchial epithelial cells

Activation of peroxiredoxin 1 by fluvastatin effectively protects from inflammation and SARS-CoV-2

AMPactivated protein kinase phosphorylation of angiotensin-converting enzyme 2 in endothelium mitigates pulmonary hypertension

Risk factors of severe disease and efficacy of treatment in patients infected with COVID-19: A systematic review, Meta-analysis and meta-regression analysis

Propofol prevents human umbilical vein endothelial cell injury from Ang II-induced apoptosis by activating the ACE2-(1-7)-Mas axis and eNOS phosphorylation

Preservation of glucagon-like peptide-1 level attenuates angiotensin II-induced tissue fibrosis by altering AT1/AT 2 receptor expression and angiotensin-converting enzyme 2 activity in rat heart

Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19

Targeting heparan sulfate proteoglycan-assisted endocytosis as a COVID-19 therapeutic option

Pioglitazone upregulates hepatic angiotensin converting enzyme 2 expression in rats with steatohepatitis

The protective effects of betacasomorphin-7 against glucose -induced renal oxidative stress in vivo and vitro

Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis

Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome

In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19

Alteration of cardiac ACE2/ Mas expression and cardiac remodelling in rats with aortic constriction

Upregulation of angiotensin (1-7)-mediated signaling preserves endothelial function through reducing oxidative stress in diabetes

ACE2 activity was increased in atherosclerotic plaque by losartan: Possible relation to antiatherosclerosis

Longitudinal alteration of circulating dendritic cell subsets and its correlation with steroid treatment in patients with severe acute respiratory syndrome

Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice

AHU377+Valsartan (LCZ696) modulates renin-angiotensin system (RAS) in the cardiac of female spontaneously hypertensive rats compared with valsartan

Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou

Vitamin D attenuates lung injury via stimulating epithelial repair, reducing epithelial cell apoptosis and inhibits TGF-beta induced epithelial to mesenchymal transition

Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2

Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats

Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression

Role of AMP-activated protein kinase in mechanism of metformin action

Association of peroxisome proliferator-activated receptors/retinoic acid receptors with renal diseases

Effect of all-trans retinoic acid treatment on prohibitin and renin-angiotensin-aldosterone system expression in hypoxia-induced renal tubular epithelial cell injury

The expressional disorder of the renal RAS mediates nephrotic syndrome of male rat offspring induced by prenatal ethanol exposure

Glucocorticoids induce the production of the chemoattractant CCL20 in airway epithelium

Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: Evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2

Effects of vitamin D supplementation on renin and aldosterone concentrations in patients with advanced heart failure: The EVITA trial

Vitamin D and airway infections: a European perspective

COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: No need for interruptions or changes in ongoing chronic treatments

Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections

25-Hydroxycholesterol is a potent SARS-CoV-2 inhibitor